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ABSTRACT 
Introduction Functional bowel disorders (FBDs) are gastrointestinal (GI) conditions based on 
patient-reported symptoms. Irritable bowel syndrome (IBS) is the most common FBD and 
despite extensive research on IBS, pathophysiology, etiology, and treatments for FBDs are still 
being researched. Treatment of FBDs involves a range of therapies including pharmaceutical 
treatments, psychological treatment, and lifestyle interventions like physical activity and dietary 
interventions. The evidence for efficacy of lifestyle interventions is still sparse. Integrative 
Medicine (IM) is a medical specialty that emphasizes lifestyle interventions, including dietary 
therapies. Studying lifestyle interventions in an IM clinic is useful because IM therapies are often 
sought out in addition to conventional medical treatment, thus patients may be more motivated to 
follow recommendations given by providers. The aims of this study include describing the 
interventions for FBDs in an IM clinic at an academic medical center (University of Kansas 
(KU)), and determining if the FBD interventions were effective. Finally, because little is known 
about the nutritional status (micronutrient) of patients with FBDs, we describe the vitamin and 
mineral status (vitamins B6, B12, D and zinc, magnesium and copper) of FBD patients. Methods 
This was a retrospective chart review in a population of 74 IM patients at KU IM. Charts were 
reviewed to collect data about FBD interventions, demographics, symptoms measurement (via 
medical symptoms questionnaire (MSQ), and micronutrient status. Results IM providers used 9 
common interventions: elimination diets, vitamin/mineral supplementation, GI-related 
supplementation (probiotics, etc.), magnesium supplementation, non-dietary lifestyle 
intervention, GI-related prescriptions, water, referral to other healthcare providers, and fermented 
foods. The 3 most common interventions for patients with FBDs were (in descending order): 
elimination diets, vitamin/mineral supplementation and GI-related supplementation. FBD 
interventions by IM practitioners were effective (75.4% of patients had symptom improvement). 
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For all patients, digestive tract symptoms improved by an average of 3.0 points (p<0.0000001) 
on a scale from 0-28. Symptoms of IBS patients also improved significantly: IBS-C (p=0.005), 
IBS-D (p=0.0004), and IBS-M (p=0.02). Micronutrient status of FBD patients was generally 
adequate except for vitamin D deficiency among 23% (n=17) of FBD patients. Most patients 
(50.7%, n=36) had elevated levels for vitamin B6 and several (14.9%, n=11) had elevated 
vitamin B12 levels; both vitamins being elevated were likely related to patients taking nutritional 
supplements before their IM consultation. Conclusion IM interventions for FBD primarily center 
on diet and nutrition-based interventions. These interventions are effective for lowering GI-
related symptoms; GI specialists should consider referring IBS patients to RDNs who are skilled 
at elimination and exclusion diets and may be knowledgeable about dietary supplement use and 
monitoring. Micronutrient status of FBD patients in this IM clinic was adequate except for 
vitamin D deficiency. Nutritional adequacy may be related to baseline supplement intake prior to 
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I. Significance of Nutrition for Functional Bowel Disorders in Integrative Medicine 
Functional bowel disorders (FBDs) include irritable bowel syndrome (IBS), functional 
bloating (FB), functional constipation (FC), functional diarrhea (FD), and FBD not otherwise 
specified (FBD-U) [1]. Conventionally, FBDs are diagnosed based on patient-reported 
gastrointestinal (GI) symptoms despite a lack of physically identifiable etiology, but the idea that 
FBDs lack physical abnormalities may be an outdated concept [2]. IBS – the most common FBD 
– is characterized by either constipation-dominance (IBS-C) or diarrhea-dominance (IBS-D) or 
mixed symptomatology (IBS-M), and patients’ symptoms are related to defecation [3].  
About 11% of adults, worldwide are diagnosed with IBS. In North America, the most 
likely prevalence range is between 10-15% [4]. The syndrome is more common in women [3] 
and those of middle age. IBS has a detrimental effect on quality of life in those who report 
symptoms [5].  
In addition to FBDs decreasing patients’ quality of life, they also pose a burden on 
primary care physicians and gastroenterologists who spend more time caring for these patients 
relative to sicker patients [6]. In addition to the time burden, FBDs also pose a financial burden 
on patients [7]. Although the direct and indirect costs per patient of FBDs vary [8], the overall 
annual cost of FBDs in the US is likely more than $26 billion US dollars [9]. Interestingly, IBS 
experts more accurately diagnose IBS than non-expert practitioners, and experts spend less 
money on testing than non-experts to reach an accurate diagnosis ($297 vs. $658) [10].  
IBS treatment includes both lifestyle recommendations (diet and physical activity), 
medication recommendations [11 12], and other therapies [13]. Most patients report more 
confidence that lifestyle recommendations would help them, but patients are more likely to 
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adhere to medication recommendations [11]. Although nutrition-based therapies and treatments 
for FBDs exist, researchers have not conducted a comprehensive investigation of the 
effectiveness of these interventions. Efficacy of these interventions has been measured in various 
settings, but the effectiveness of these therapies in an integrative medicine clinical setting is 
unknown. Patients in an integrative medicine setting may be more willing to make lifestyle 
changes because they seek this additional healthcare, thus I chose an integrative medicine clinic 
to study the efficacy of lifestyle interventions. 
II. Functional Bowel Disorders: Definition, Prevalence, Diagnosis and Treatment 
FBDs are digestive disorders that include IBS, functional bloating (FB), functional 
constipation (FC), functional diarrhea (FD), FBDs not otherwise specified (FBD-U) [1], and 
more recently, opioid-induced constipation [14]. FBDs are clinical conditions without a known 
structural or biochemical basis. Instead, FBDs are based on clinical, patient-reported symptoms 
of the middle and lower GI tract. Prevalence of FBD Functional bowel disorders is estimated 
between 10-20% of adults, worldwide [3]. A 2012 meta analysis reports IBS prevalence is about 
11% worldwide and varies from 1% to 45% among countries [15]; worldwide prevalence is 
questionable due to heterogeneous study methods [16]. IBS is most common among women and 
between the ages of 30-50 years [17]. 
Currently, providers do not agree upon specific biomarkers to diagnose IBS, and 
symptom-based diagnosis remains the standard [18]. However, IBS’s definition is debated as a 
functional disorder as some evidence suggests IBS has organic pathophysiology [19-21]. The 
physical intestinal barrier of people with IBS is altered, suggesting the condition may not be 
merely clinical [22]. Additionally, physical biomarkers like fecal short chain fatty acids [23] and 
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hydrogen sulfide in exhaled breath [24], and small intestinal bacterial overgrowth (SIBO) [25] 
are suggested by emerging research.  
De Giorgio and colleagues [26] describe IBS as a “prototype of all functional bowel 
disorders for its high prevalence worldwide and impact on patients’ quality of life.” Thus, most 
of the evidence in this literature review is from IBS-related research due to its disproportionate 
presence in the literature.  
In a survey of internal medicine physicians, family physicians, and gastroenterology 
physicians, the internal medicine physicians and family physicians reported the need to refer 
about one third of IBS patients to a gastroenterology physician [6]. Gastroenterologists reported 
that IBS patients are less ill than other patients but require more of their time [6], possibly 
reflecting some of the psychosocial effects of IBS. Thus, IBS patients pose a disproportionate 
time burden on physicians who also need to care for more critically ill patients. 
Diagnosis of FBDs is based on Rome IV criteria (i.e. fourth version). The Rome Criteria 
are established by The Rome Organization (a 501c3 tax-exempt organization) [27]. 
Gastroenterologists use the Rome Criteria as standard diagnostic criteria for IBS. The diagnostic 
criteria for FBDs, including IBS (Rome IV) are shown in Table 1. To ensure patients do not have 
more severe GI-related disease than a FBD, clinicians note “red flag” or “alarm” signs during 
their assessment. These signs include: bloody stools, symptoms that wake a patient at night, 
unintentional weight loss, use of antibiotics, and family histories like celiac disease, colon cancer 
or others [28].  
Although FBD diagnostic guidelines suggest FBD diagnosis should be based on clinical 
symptomatology and the Rome criteria, in practice the Rome criteria is used by just over 1/3 of 
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European primary care physicians [29]. Another challenge to using the Rome criteria is the 
emergence of physical biomarkers as potential diagnostic markers [30]. Proposed IBS 
biomarkers include elevated bile acid in stool and altered colonic transit time [30]. Mast cells 
have also been implicated as possible biomarkers of IBS pathophysiology [31]. 
Table 1: Rome IV Diagnostic Criteria for Irritable Bowel Syndrome [32].  
Rome IV Diagnostic Criteria* for Irritable Bowel Syndrome  
*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis 
Recurrent abdominal pain at least 1 day per week over the past 3 months associated with two or 
more of the following: 
1. Related to defecation 
2. Associated with a change in frequency of stool 
3. Associated with a change in form (appearance) of stool 
 
Treatment for FBDs differs based on the type of FBD and the accompanying 
symptomatology. Evidence for food-based therapies to improve FBD-related symptoms is 
promising [26 33]. General FBD treatments include diet changes [34], and, specifically for IBS, 
include psychological, pharmacological, diet changes, and dietary supplement treatments [35]. 
Diet therapies for IBS include avoidance of food allergies using elimination diets and changes in 
fiber or specific carbohydrate intake [33 35]. Psychological IBS treatments include short- and 
long-term psychotherapies [13]. According to The Mayo Clinic, there are two current 
pharmacological treatments approved specifically for IBS: Alosetron (Lotronex) [36] (prescribed 
for IBS-D) and Lubiprostone (Amitiza) (for IBS-C and chronic constipation) [37]. Clinicians are 
also using a new prescription medication, Linaclotide (Linzess), for IBS-C and chronic 
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constipation [38]. Other medical treatments for IBS symptoms include fiber supplements, anti-
diarrheal medications, anticholinergic and antispasmodic medications, antidepressants, 
antibiotics, polyethylene glycol (PEG) [39], lactulose [39], and psychological counseling for 
mental health features of IBS [37]. Interestingly, non-concealed placebo treatment for IBS is also 
effective at relieving symptoms [40]. Although the placebo effect is an effective IBS treatment, it 
seems to last only about 12 weeks [41].  Variable research methods for yoga as an intervention 
for IBS suggest that yoga is a safe and possibly effective adjuvant to IBS treatment [42].  Dietary 
supplement treatments for IBS include magnesium [43], melatonin [44], peppermint oil [45 46], 
probiotics and fiber supplements [45].  
III. Burden of FBDs and IBS 
A. Symptomatology of FBDs 
FBDs are characterized by symptoms that patients report to their diagnosing healthcare 
providers. IBS is specifically characterized by lower gastrointestinal symptoms, including 
bloating, cramping below the belly button, stomach pain, constipation and/or diarrhea [47]. 
When compared to asymptomatic controls and US norms, people with IBS symptoms report 
poorer physical and mental health based on the Short Form-36 (SF-36) (a quality of life 
questionnaire) [48]. Patients with FBD report symptoms including change in stool form and 
frequency, abdominal pain, bloating and/or distension, and other symptoms. See Table 2 for 





Table 2: Symptoms of Functional Bowel Disorders. Adapted from The University of Michigan 
website [47], Tack 2006 [50], Lacy 2016 [14] 
Symptoms of FBDs 
IBS symptoms 
Abdominal bloating and/or distension  
Pain in mid-to-lower abdomen 
Constipation (IBS-C and/or IBS-M) 
Diarrhea (IBS-D and/or IBS-M) 
FD symptoms 
Repeated loose or watery stools 
Possible abdominal pain/bloating (but less likely than IBS) 
FC symptoms 
Difficult, infrequent or incomplete defecation  
Possible abdominal pain/bloating (but less likely than IBS) 
FB symptoms 
Repeated abdominal fullness, feeling of trapped gas, pressure, and/or 
objective increase in abdominal circumference (distension) 
Unspecified FBD symptoms 
Symptoms do not meet IBS or other FBDs, but patient does not have 
physical evidence of disease 
Opioid-induced constipation symptoms 
Change in baseline bowel and defecation habits after starting opioid 
medications 
Less frequent bowel movements 
Increase in straining 
Feeling of incomplete evacuation 
 
B. Comorbidities of IBS 
IBS patients often have overlapping FBD-related symptoms [51]. About half of patients 




In addition to the burden of GI-related symptomatology in IBS, patients with IBS have 
higher rates of anxiety and depression [54], chronic headaches, and fibromyalgia [55]. In fact, 
anxiety independently predicts whether IBS patients seek healthcare [56]. Other conditions 
commonly seen among persons with IBS include chronic fatigue syndrome, interstitial cystitis, 
tension headaches and others [51 57 58].  
C. Quality of Life and Economic Burden of FBDs 
 Patients with FBDs and, specifically, IBS-C and IBS-D have lower health related quality 
of life (HRQOL) [7 59]. This decreased quality of life translates to increased direct costs (over 
the counter medications, cost of alternative treatments) and indirect costs (lost work productivity, 
including absenteeism and presenteeism, i.e. working while sick) [7]. 
 The costs to patients with FBDs include costs of over-the-counter and alternative 
treatments, cost and time spent for healthcare visits, time off work, and others.  Although the 
direct and indirect costs per patient of FBDs vary [8], the overall (direct and indirect) annual cost 
of FBDs in the US is likely more than $26 billion US dollars [9]. Specifically, IBS-D has a 
significantly higher cost burden for medical service use (not pharmaceuticals) when compared to 
matched controls [60]. 
IV. Factors Contributing to Diagnosis of FBDs 
Functional bowel disorders (FBDs) are a group of conditions that includes irritable bowel 
syndrome (IBS), functional bloating (FB), diarrhea (FD), functional constipation (FC), and 
unspecified functional bowel disorders (FBD-U) [61]. FBDs are not life-threatening conditions, 
but they negatively impact patients’ the quality of life [62]. FBDs are diagnosed based on 
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patient-reported gastrointestinal (GI) symptoms despite a lack of physically identifiable etiology. 
Although IBS diagnosis is often called a “diagnosis of exclusion,” IBS experts suggest the 
condition is not a disease of exclusion [10]. IBS is the most common FBD. Patients with IBS 
report pain and their symptoms are related to defecation or a change in bowel habits. IBS 
symptoms are characterized by either constipation-dominance (IBS-C), diarrhea-dominance 
(IBS-D), mixed symptomatology (IBS-M), or are unclassified (IBS-U) [14]. IBS has both 
complex pathophysiology and treatment [63]. 
Diagnosis of FBDs can be difficult; the various FBDs share common symptomatology 
with other GI conditions [64-66]. For example, both FC and IBS-C have constipation in Rome 
criteria for diagnosis, but a distinction between them is the presence of pain with IBS-C 
compared to chronic constipation [38].  
A. Symptom Profile 
Altered gastrointestinal function and accompanying symptoms define FBDs. The Rome 
IV Criteria is the most current and widely accepted diagnostic criteria for FBDs. See Table 1 for 
Rome IV Criteria for IBS diagnosis [32]. IBS is distinct from other FBDs because IBS patients 
more often report pain and report symptoms related to defecation. 
B. Psychological Health, Sleep and FBDs 
Psychological abnormalities are common among persons with IBS, including anxiety [67 
68], depression [68], somatization [68 69], and hypochondria [35]. Persons with FBDs score 
higher on personality measurements of neuroticism and introversion [70]. IBS patients more 
often report chronic stressors [71], and their perceived stress is negatively associated with quality 
of life factors [72]. In fact, anti-depressants effectively alleviate IBS symptoms (both physical 
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and psychological) [73]. Although persons with IBS have psychological abnormalities, evidence 
from a case-control sleep study of IBS patients suggests IBS patients have higher sympathetic 
dominance. Thus, the characterization of increased anxiety and sympathetic dominance may be 
inherent and not solely psychosocial [74 75]. Psychological aspects of FBDs are complex, and 
we do not know whether psychological abnormalities initiate FBD pathophysiology or FBD-
related symptoms lead to psychological problems. 
IBS patients also exhibit disturbed sleep [76]; they sleep more hours, but they have more 
waking episodes and report less restful sleep. In addition to abdominal symptomatology, IBS 
affects quality of life related to sleep habits.   
C. Genetics and FBDs 
Tumor necrosis factor superfamily member 15 (TNFSF15), which has been called the 
“IBS gene” [19], is associated with IBS. Other IBS-related genes are linked to inflammation, 
neurotransmitters and synthesis of bile acids, and can play roles in IBS pathophysiology [19]. In 
a systematic review, Infante-Molina [77] reported that 44% of non-celiac gluten sensitivity 
(NCGS) patients (often exhibiting IBS-like symptoms) had HLADQ2/DQ8 (celiac-related) 
haplotypes. Thus, genes likely play a role in IBS pathophysiology, but more research is needed 
to make clinical recommendations for genetics-based treatment. 
D. Food intolerances/sensitivities and allergies in Functional Bowel Disorders 
About 50% of patients with IBS have true, IgE-based food allergies [78], and the idea 
that persons with IBS may have underlying food sensitivities is not new [79 80].  Common food 
sensitivities include gluten intolerance or sensitivity, wheat intolerance or sensitivity, lactose 
intolerance, fructose malabsorption, and sensitivity to a group of carbohydrates referred to as 
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“FODMAPs” (fermentable oligosaccharides, disaccharides, monosaccharides and polyols) [33 
81 82]. FODMAPs are a group of short-chain, easily fermentable carbohydrates that can 
contribute to IBS symptoms. Persons with food sensitivities who have IBS can be alleviate their 
symptoms by eliminating the offending food or foods [33]. Lowering FODMAPs in the diet 
reduces IBS symptoms [83]. Other food components that can elicit IBS-like symptoms include 
benzoates, amines, glutamate, and salicylates [26].  
In 2015, Pasqui and colleagues [84] proposed a therapeutic algorithm to diagnose and 
treat food allergy and intolerances related to functional GI symptoms. Their algorithm is a 
“diagnostic-therapeutic protocol” that is used to assess food allergy or intolerance. Their 
therapeutic algorithm guides a practitioner through presenting symptoms (GI-related) and 
recommended lab testing: IgE allergy testing, lactose breath testing, IgA measurement, and 
endoscopic testing. Based on the results of lab testing, recommendations for therapies are made 
(lactose-free diet, gluten-free diet or elimination of any other allergenic food).  
In a tutorial by Mullin and colleagues [33] that reviews nutritional therapies for IBS, 
investigators suggested that addressing adverse food reactions and intolerances (e.g. lactose, 
gluten, wheat, FODMAPs) and using dietary supplements (e.g. peppermint oil, herbs, pre- and 
probiotics, fiber) are all evidence-based therapies for IBS. They provided a nutrition-based care 




Figure 1: Care algorithm for using diet-related interventions for patients with IBS. Figure 
adapted from Mullin et al 2014 [33]. IBS, irritable bowel syndrome; CD, celiac disease. 
RDN, registered dietitian-nutritionist. GFD, gluten-free diet; FODMAP, fermentable 
oligo- di- monosaccharides and polyols; SIBO, small intestinal bacterial overgrowth.  
yes no 
IBS symptoms from food 
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foods. CD ruled out. 
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Figure 2: Diet-related care algorithm for patients with GI symptoms. Adapted from Pasqui 2015 
[84]. GI, gastrointestinal. 
E. IBS and Non-Celiac Gluten Sensitivity 
IBS symptoms often overlap with symptoms reported by persons with NCGS [85], and 
some suggest that a portion of IBS patients have NCGS [86]. NCGS is of growing concern for 
healthcare providers in the US and around the world [77 87-89]. Doctors and other diagnosing 
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healthcare professionals are beginning to characterize the diagnostic criteria for NCGS as distinct 
from Celiac Disease (CD) and wheat allergy [90]. In persons with NCGS, gluten appears to 
trigger the innate immune system [90], which may help explain the effectiveness of elimination 
diets based on IgG food sensitivity testing [91]. Prevalence of NCGS may range between 0.5% 
and 13%, the higher range exceeding that of CD prevalence [77]. However, gluten may not be 
the cause of patients’ symptoms but more of a nocebo effect [92].  
Presence of both celiac-related genes (HLA-DQ2) and elevated IgG anti-gliadin 
antibodies in persons without CD diagnosis are more predictive of the effectiveness of a gluten-
free diet than either marker alone (56% positive predictive value compared to 44% and 45% of 
each HLA-DQ2 and gluten antibodies, respectively). In other words, patients with both HLA-
DQ2 genes and elevated anti-gliadin antibodies with IBS-D are more likely to benefit from a 
gluten-free diet than those without the celiac-related gene and antibody markers [93 94]. 
However, evidence suggests that expression of HLA-DQ2 or DQ8 may not be a useful marker of 
wheat sensitivity [95]. NCGS is one of many possible contributors to GI symptoms in IBS 
patients.  
Adherence to a gluten-free diet is variable, even in patients with CD adherence ranges 
between 42-91% [96]. Thus, adherence will likely vary among persons with NCGS. Leffler and 
colleagues [97] found that self-reported adherence and serological measurements of adherence to 
a gluten free diet were associated, therefore, self-reported adherence may be a useful proxy 




V. Etiology and Pathophysiology of FBDs 
A. Etiology of IBS 
The etiology of IBS is elusive, but several factors have been proposed to contribute to 
IBS.  Evidence suggests an imbalance of the autonomic nervous system (ANS) may contribute to 
IBS pathophysiology [98]. Patients with IBS-C have lower parasympathetic modulation based on 
heart rate variability (HRV) measurement [99]. However, evidence for HRV in IBS patients 
versus controls varies widely, especially when comparing IBS subgroups [100 101]. Evidence in 
children with IBS demonstrates that HRV biofeedback (HRVB) alleviates IBS-related symptoms 
[102]. Mucous layer damage may also be a contributing cause of both IBS and inflammatory 
bowel disease (IBD) [103]. 
Historically, IBS was believed to be a predominantly psychosomatic condition. However, 
in the last decade, evidence suggests that alterations in the microbiota are associated with IBS 
pathophysiology [104 105]. Related to this idea: post-infectious IBS is triggered after a GI 
infection [19] and patients’ IBS symptoms are alleviated by antibiotics [106]. In fact, IBS-D 
patients who took the probiotic Lactobacillus brevis KB290 with beta carotene for 12-weeks 
reported less severe abdominal pain and higher levels of circulating interleukin-10 (an anti-
inflammatory cytokine) [107] Thus, IBS may be an infectious disease [106]. See Table 3 for 
background on IBS pathophysiology. 
B. Pathophysiology of Irritable Bowel Syndrome 
The full picture of IBS pathophysiology remains unknown, but many factors contribute to 
IBS pathophysiology [19]. See Table 3 for a short summary of different aspects of IBS 
pathophysiology. These physical abnormalities support that IBS may not be “idiopathic.”  
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Table 3: Short summary of IBS pathophysiology  
IBS Pathophysiology 
Altered GI motility1 or “Motor 
Dysfunction”2 
High-amplitude propagated contractions (HAPCs) are common in 
IBS-D pathophysiology (rare in IBS-C). Similarly, transit time is 
longer for persons with IBS-C and shorter for IBS-D. Both IBS-D 
and IBS-C patients report incomplete bowel evacuation. Other data 
suggest pelvic floor abnormalities as contributing to IBS symptoms 
[108].  
Autonomic Nervous System 
Dysregulation2 
IBS-D patients have abnormal sympathetic adrenergic nervous 
system activity while IBS-C patients have abnormal vagal 
parasympathetic activity.  
Visceral hypersensitivity1 
Persons with IBS have increased sensitivity in their GI tract [109]: 
esophageal, gastric, small intestinal, colonic and rectal [19]. This 
increased sensitivity has been associated with increased stress and 
food ingestion [19] and is related to both internal and external 
(environmental) factors. 
Gut-Brain Interaction1 
Hormones facilitate the communication between the gut-brain axis. 
Specifically, corticotropin-releasing hormone (CRH) controls stress 
communication. Evidence from brain imaging research shows 
increased brain activation with GI distension [19].  
Inflammation1 
The intestinal mucosa of IBS patients has elevated inflammatory 
markers like T-lymphocytes, neutrophils, mast cells, and plasma 
cells [19].  
Post-infectious low-grade 
inflammation1 
PI-IBS is characterized by IBS symptoms that do not meet Rome 
criteria but are preceded by any two of the following: fever, emesis, 
diarrhea, culture positive for GI bacterial overgrowth. Low-grade 
inflammation characterizes PI-IBS pathophysiology [19]. 
Small Intestinal Bacterial 
Overgrowth (SIBO)3 
SIBO shares similar symptomatology of IBS and some suggest that 
IBS may actually be an infectious disease [106]. 
Genetic Factors of Inflammation1 
Genetic factors related to IBS pathophysiology are characterized by 
inflammation, neurotransmitters and synthesis of bile acids. 
TNFSF15 is called the “IBS gene.” Variants of genes TLR9, IL-6 
and CDH1 were associated with increased risk for PI-IBS [110]. 
Controversy exists for the relationship between IBS and genetic 
variants of the IL-10 gene. 
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Immunologic Factors1 
The immune system is activated in IBS leading to increased 
expression of immune factors: TLR2, TLR4, IL-1, IL-8, TLR5, 
TLR9, IL-6, CDH1. 
Genetic Factors of 
Neurotransmitters and Cytokines1 
NT and cytokine-related genetic polymorphisms associated with 
IBS: SLC6A4 (a SERT gene), GNbeta3, NPSR1, FAAH, and 
C385A. 
Genetic Factors of Bile Acid 
Synthesis1 
Bile acid synthesis-related genetic polymorphisms associated with 
IBS: KLB gene (rs17618244), TGR5. 
Altered Microbiota1 
Altered GI bacteria may lead to IBS pathophysiology. SIBO is 
common in certain IBS subsets. Elevated dysbiotic bacteria and 
lower lactobacillus and bifidobacterium are common in IBS patients 
[111].  
Diet-related Factors1 
Food allergies & intolerances: Little evidence exists for the role of 
food allergies in IBS pathophysiology. Evidence supports the role 
of intolerances in IBS pathophysiology (though still debated) due to 
elimination of certain foods resulting in alleviation of IBS-
symptoms.  
Altered absorption: Poor absorption of certain food components, 
like short-chain carbs (e.g. fructose) and FODMAPs (fermentable 
oligosaccharides, disaccharides, monosaccharides, and polyols) can 
lead to IBS-symptoms. Gut flora also contributes to altered nutrient 
absorption and gas-forming fermentation (leading to IBS 
symptoms). 
Gluten intolerance: Conflicting evidence exists [112 113] for the 
role of gluten intolerance in IBS-related symptoms. Some report 
gluten withdrawal alleviates IBS symptoms [113] while others 
refute that claim [112].  
Enteroendocrine Cells1 
Gastrin, secretin, stomatostatin, cholecystokinin, chromogranins, 
and serotonin are all bioactive substances released by 
enteroendocrine cells. Abnormal levels of some of these 
compounds are found in IBS patients. E.g. elevated release of 
serotonin in IBS-D and PI-IBS; elevated 5-HT is associated with GI 
inflammation; abnormal levels of chromogranin A are found in IBS 
patients.  
Intestinal Barrier4 
Patients with IBS-D and PI-IBS have increased intestinal 
permeability (altered GI barrier function and risk of bacterial 
translocation). Zonula occludins (ZO) proteins play a role in gut 
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barrier function and zonulin specifically regulates tight junctions. 
Triggers of altered intestinal permeability: stress, foods, infections. 
Altered bile acid metabolism5 
Abnormalities in bile acid metabolism are common in patients 
with IBS-D [2]. Patients with IBS-D often have elevated bile 
acid levels in their stool [114].  
1Lee 2014, 2Hasler 2011, 3Thompson 2016, 4Camillerei 2012,  5Holtmann 2016 
IBS, irritable bowel syndrome; GI, gastrointestinal; HAPCs, High-amplitude propagated 
contractions; IBS-D, diarrhea-dominant IBS; IBS-C, constipation-dominant IBS; CRH, 
corticotropin-releasing hormone; PI-IBS, post-infectious IBS; SIBO, small intestinal bacterial 
overgrowth; TLR, toll-like receptor; IL, interleukin; CDH1, cadherin-1; NT, neurotransmitter; 
SLC6A4, Solute Carrier Family 6 Member 4; SERT, serotonin transporter; GNbeta3, A gene 
associated with functional dyspepsia (aka GNβ3); NPSR1, Neuropeptide S Receptor 1; FAAH 
C385A, fatty acid amide hydrolase C385A; KLB, klotho beta; TGR5, G protein-coupled bile 
acid receptor 1; FODMAPs, fermentable oligosaccharides, disaccharides, monosaccharides and 
polyols; ZO, zonulin.  
 
VI. Modifiable Lifestyle Factors for FBDs 
Some lifestyle approaches can alleviate FBD-related symptoms. Those include dietary 
approaches like limiting or eliminating specific food triggers, psychotherapy, stress reduction, 
and others [33].  In fact, ingestion of food, alone, can trigger IBS symptoms [115]. 
A. Dietary Approaches, Food Intolerances, Food Sensitivities and IBS 
i. Elimination Diets 
Elimination or “exclusion” diets have been used for years to alleviate IBS symptoms 
[116]. Elimination diets can help identify both IgE and non-IgE-mediated food allergies or 
sensitivities [117]. The European Academy of Allergy and Clinical Immunology (EAACI) 
recommends a 2-4 week elimination diet is sufficient to identify food allergies for IgE-related 
food allergies, while non-IgE-related allergy (food sensitivity) requires up to 6 weeks [117]. For 
non-IgE-mediated food sensitivities, studies in children suggest nearly all of patients (98.4%) 
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report symptom improvement after 4 weeks [118]. To my knowledge, no comparable recent data 
[119] exist for adults regarding symptom improvement following elimination diets for non-IgE-
mediated GI food sensitivities.   
In addition to elimination diets, clinicians use other methods to identify food sensitivities. 
Food sensitivity laboratory testing includes the mediator release test (MRT®) testing, serum IgG 
testing, and others. Symptoms of patients with IBS improve when they eliminate foods that are 
identified as abnormal per serum IgG testing [120]; personalized elimination diets based on IgG 
blood testing improved IBS-related symptoms and self-reported quality of life in IBS patients 
[91]. Little is known about the efficacy of treatment based on the other methods of testing.  
In 2014 Kabbani and colleagues [121] created a diagnostic model to guide healthcare 
practitioners to diagnose CD, NCGS, or Non-Celiac Enteropathy. The algorithm starts with 
identifying patients who report symptoms responsive to a gluten-free diet [121], then leads the 
clinician through lab testing algorithms, and finally ends with potential gluten-related diagnoses 
(e.g. CD, NCGS, serological-negative CD, non-celiac enteropathy and indeterminate diagnosis).  
Beyond diagnostic criteria, Pasqui and colleagues [84] created a diagnostic and 
therapeutic algorithm to assist healthcare practitioners in the accurate diagnosis and therapy for 
adverse food reactions. They distinguish food allergies, food intolerances, sensitivities, and 
different methods to diagnose these conditions. Additionally, they provide algorithms to assist 
decision-making for therapeutic diet recommendations. Pasqui and colleagues’ [84] diagnosis 
and dietary care algorithm (see Figure 2), leads to recommendations for use of specific 
elimination diets.  
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ii. Low FODMAP Diet 
Similar to the use of tailored food withdrawal diets, lowering intake of FODMAP foods 
alleviates IBS-related symptoms [112 122 123]. Clinical evidence suggests that a low-FODMAP 
diet can alleviate IBS symptoms [83], and one review concluded that evidence for use of low-
FODMAP diets in FBDs is “sufficiently strong to recommend its widespread application” [82]. 
Foods with high amounts of FODMAPs contain easily fermentable, short-chain carbohydrates. 
Table 4 lists foods with high amounts of different categories of FODMAPs [33].  
Table 4: Common foods high in FODMAPs [33 84] 








































































Although low-FODMAP diets are effective for IBS, evidence from one randomized 
controlled trial suggests that a low-FODMAP diet was no more effective at improving IBS 
symptoms than traditional dietary advice (eating smaller meals at consistent times, decreasing 
fat, indigestible fiber, caffeine, and gas-producing foods like cabbage, onions and beans) [124]. 
Concerns about a low-FODMAP diet include an unknown effect on the GI flora, long-term 
effects and nutritional adequacy [122 125]. 
iii. Gluten-Free Diet Non-Celiac Gluten Sensitivity, Non-Celiac Wheat Sensitivity or Non-Celiac 
Wheat Protein Sensitivity 
NCGS is a new condition of growing concern for healthcare providers in the United 
States and around the world [77 86 88-90 112 121 126-129]. Published reviews related to NCGS 
span disciplines that include gastroenterology [86 121 128], clinical nutrition [126], nutritional 
metabolism [130 131], nursing [127], and cellular and molecular immunology [89]. Similar to 
IBS, NCGS is more common among women and between the ages of 30-50 years [130]. NCGS 
diagnosis is difficult due to symptomatic similarities between NCGS and CD [121]; some 
suggest that a subpopulation of IBS patients likely have NCGS [86]. Doctors, Nurse 
Practitioners, and other diagnosing healthcare professionals are just starting to characterize 
diagnostic criteria for non-celiac gluten sensitivity, which is important because NCGS is distinct 
from CD and wheat allergy [90 121 127]. Recognition of NCGS is recent enough that there is 
still discussion regarding the accurate terminology for the condition [132]. Nomenclature 
surrounding the condition has been discussed, suggesting “Non-Celiac Wheat Sensitivity” as a 
more appropriate label than “Non-Celiac Gluten Sensitivity” since the exact component of wheat 
that elicits symptoms has not been identified [132].  
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In a double blind, randomized, placebo-controlled trial, Biesiekierski and colleagues 
[133] tried to determine whether gluten intake could elicit symptoms in persons without CD. The 
investigators studied a group of 34 patients with IBS and non-celiac who controlled their 
symptoms on a gluten-free diet. At baseline, patients reported symptoms on a visual analog scale 
for pain, bloating, stool consistency satisfaction, and tiredness. Researchers also measured GI 
biomarkers of inflammation, immune activation and injury. Participants followed a gluten free 
diet throughout the 6-week trial and were divided into two groups: one group consumed gluten-
containing bread and muffins, and the other was given gluten-free bread and muffins. After the 
6-week intervention, participants again completed the symptom reports and biomarker lab tests. 
Sixty percent of the participants given gluten reported significantly poorer symptom control 
(overall symptoms, pain, bloating, stool consistency satisfaction and tiredness) while fewer of 
the placebo group (40%) reported poorly controlled symptoms. Investigators concluded that 
NCGS likely exists, but the mechanism remains unknown [134].  
Data from a more recent study by Biesiekierski and colleagues [112] with 37 subjects 
suggest there is no effect of gluten on patients with self-reported NCGS when compared to 
improvement of symptoms following a low FODMAPs diet. Symptoms were well controlled 
following the low-FODMAPs diet, but upon the “food challenge” period (reintroducing gluten), 
symptoms were not significantly different between the study arms. Although data from clinical 
trials are variable, it is reasonable to consider a gluten-free diet for patients with IBS symptoms. 
However, it will be important to characterize patients who benefit the most from this dietary 
treatment.   
De Giorgio and colleagues [26] summarized results from double-blind placebo-controlled 
trials among non-celiac patients with gluten or wheat sensitivity and IBS symptoms [112 134-
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138]. They also summarized the clinical trial results for low FODMAP diets’ effectiveness in 
IBS symptoms [83 139-144].  
Fasano and colleagues [86] created a figure showing the varying pathogenesis of gluten-
related disorders [autoimmune, allergic and non-autoimmune/non-allergic (possibly involving 
the innate immune system)]. See Figure 3 below.  
 
Figure 3: Characterization of the pathogenesis of gluten-related disorders. Figure adapted from 
Fasano and colleagues, 2015 [86]. WDEIA: wheat-dependent induced anaphylaxis. 
Czaja-Bulsa [126] created an algorithm to understand if the etiology of a patient 
presenting with IBS-like syndrome, includes a gluten-related disorder (CD, wheat allergy, 
NCGS), IBS, bacterial overgrowth, or a non-gluten adverse food reaction (lactose intolerance, 






















Figure 4: Modified from Czaja-Bulsa, 2015: Clinical presentation of IBS to guide clinical action 
[126]. IBS: Irritable Bowel Syndrome; FODMAPs: fermentable oligosaccharides, disaccharides, 
monosaccharides and polyols. 
B. Psychiatric Health (Anxiety and Depression)  
Anxiety and depression are common in FBDs [54]. Evidence from a recent meta analysis 
of persons with IBS suggests that these patients benefit from both short- and long-term 
psychotherapy [13]. Thus, persons with IBS may be recommended to seek therapy.  
C. Stress and FBDs 
It is well known that stress and FBDs are related. In fact, psychological stressors trigger 
IBS symptoms [33 145]; and women with IBS more often report early traumatic life events 
(physical, emotional, and sexual abuse) than women without IBS (p<0.001) [146]. To further 




















have a significantly higher prevalence of IBS compared to controls [147] with their stressful 
work environments explaining the relationship. 
VII. The Placebo and Nocebo Effects and IBS  
 There is a placebo effect on IBS symptoms, however Spiller and colleagues [41] found 
that the placebo effect for IBS patients diminishes after 12 weeks. Thus, a follow up period 
beyond 12 weeks may be ideal for the assessment of the efficacy of IBS-related interventions.  
 As mentioned above, the nocebo effect of gluten-free diet may contribute to its seeming 
effectiveness [92], but this should be further explored.  
 Based on results from a systematic review, there is a placebo effect of psychotherapy on 
IBS patients that is similar to that of other IBS treatments (medications, dietary and alternative 
interventions) [148].  
VIII. Alterations of the Gastrointestinal Environment and FBDs 
Small Intestinal Bacterial Overgrowth (SIBO) is a condition defined as an overgrowth of 
bacteria with a minimum of 105 colony-forming units (CFU) per milliliter on a culture of an 
upper gastrointestinal aspirate [149]. SIBO symptoms are similar to those with IBS, so persons 
with SIBO may be misdiagnosed as having IBS [149]. There is evidence of a direct relationship 
between IBS and SIBO [150]. Thus, SIBO should be considered as a possible contributing factor 
in persons reporting IBS symptoms, but diagnostic-testing methods for SIBO needs improvement 
[151].  
One factor that affects SIBO risk is patients’ use of Proton Pump Inhibitors (PPIs) to 
control reflux symptoms. By blocking acid production in the stomach, PPIs change the pH of the 
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stomach and increase patients’ risk for SIBO [152]. Patients on long-term PPIs should be 
monitored for IBS symptoms that may be affected by an elevated pH and, as a result, increased 
susceptibility for SIBO. 
IX. Nutritional Considerations and IBS 
A. Nutritional Status and IBS 
With several dietary interventions for IBS treatment, some investigators have looked at 
the possible connections between nutrient intake and IBS. New evidence suggests that the 
severity of IBS symptoms is inversely related to vitamin D status in persons with IBS and that 
the majority of people with IBS may have vitamin D deficiency [153]. Magnesium is another 
possible nutrient deficiency among persons with IBS as magnesium supplementation can 
effectively alleviate symptoms of IBS [43]. A study of the 7-day dietary and nutrient intake of 
IBS patients suggests that patients with IBS have a lower intake of vitamin B6 but no other 
nutrients emerged as significant [154].  
Nutritional deficiencies are more common in CD than NCGS. In a retrospective chart 
review, Kabbani and colleagues [121] found that 57.4% of CD patients had nutrient deficiency 
(defined as one or more of the following: vitamin D, iron deficiency anemia, vitamin B12 or zinc 
deficiency) compared to patients with NCGS. Persons with CD may be nutritionally deficient 
due to their restricted diet (gluten withdrawal removes b-vitamins from the diet) or from 
malabsorption inherent in CD.  
Magnesium is a mineral (Mg2+) with multiple functions: enzyme cofactor, chelates 
adenosine triphosphate (ATP), competes with calcium (Ca2+) for binding sites to regulate 
intracellular and extracellular calcium concentrations, and other functions. Homeostasis of 
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magnesium is maintained by balancing gastrointestinal absorption with renal excretion of the 
mineral. Magnesium deficiency alters gut microbiota and contributes to anxiety pathophysiology 
in mice [155]. Magnesium-deficient mice have abnormalities in the hypothalamic-
pituitaryadrenal (HPA) axis, leading to increased anxiety-related behaviors [156], and these 
magnesium-deficient mice serve as a model to study anxiety [156]. Comorbidity of IBS includes 
other diseases that are characterized by magnesium deficiency including anxiety [156], chronic 
headache [157], fibromyalgia [158]. Thus, it is reasonable to suggest that magnesium deficiency 
may play a role in patients with both IBS and anxiety.  
Other nutrients may be implicated in the pathogenesis of IBS. In zinc metabolism, 
specifically, IBS pathogenesis may follow a different course depending on the patient’s blood 
levels of zinc or the amount of fecal zinc excretion [159]. Deficiencies of both zinc and 
magnesium have been suggested as possible factors implicated in pathophysiology of 
fibromyalgia, a comorbidity of IBS, but there is not similar evidence for the pathophysiology of 
IBS or other FBDs [160]. 
X. Patient Satisfaction with IBS Treatment 
 Patients with severe IBS were interviewed (n=10, 4 women, 5 men, 1 transgender) about 
their healthcare encounter experiences for treatment of IBS [161]. These patients had negative 
emotions related to both their symptoms and the perception that their healthcare providers did 
not believe the reality of their symptoms. In addition to these negative experiences, these IBS 
patients demonstrated strengths like perseverance (not giving up), finding solutions, and seeking 
information and social support. Thus, patients with IBS may be more likely to seek alternative 
therapies for their symptoms.  
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 Dorn and colleagues [162] developed and validated an instrument to determine patients’ 
satisfaction with IBS care (IBS-SAT). They measure 5 subscales, including: connection with 
provider, education, benefits of visit, office attributes (wait time, office staff, etc.), and access to 
care. The IBS-SAT would be a helpful tool to determine why patients might seek care outside of 
conventional healthcare.  
XI. Integrative Medicine: Practice, Patients, and Interventions 
Definitions of integrative medicine (IM) vary widely. Hu and colleagues [163] 
summarized 17 different IM definitions by measuring the frequency of 11 different components. 
The 4 most common were that IM: 1) has aspects of both complementary and alternative 
medicine (CAM) and conventional medicine; 2) emphasizes the importance of the therapeutic 
relationship between practitioner and patient; 3) emphasizes goals of health and healing; 4) takes 
a holistic approach to health. In another study of 29 IM centers across the U.S. (The Bravewell 
Report), one IM program described their approach to patient care as “a commitment to find and 
treat the root causes of the patient’s condition.” [164]  
The Academic Consortium for IM and Health states that “integrative medicine and health 
reaffirms the importance of the relationship between practitioner and patient, focuses on the 
whole person, is informed by evidence, and makes use of all appropriate therapeutic and lifestyle 
approaches, healthcare professionals and disciplines to achieve optimal health and healing” 
[165]. And, IM practitioners spend more time with patients [166] so an IM clinic is an optimal 
setting to care for and study FBD patients, especially since GI specialists have limited time [6].  
One of the foundational therapies used in IM practice is nutrition-based interventions 
[164]. Since many IM interventions are based on lifestyle changes (e.g. sleep, exercise, diet), an 
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IM clinic is an appropriate population to investigate the impact of dietary interventions on 
persons with FBDs. For example, adherence to a Mediterranean style diet has a positive impact 
on the gut microbiota of consumers [167], which may impact IBS symptoms. 
Spending on alternative medicine appointments is estimated around $10 billion US 
dollars annually in the US [168 169] and tens of billions more, if you include products, classes 
and materials [169]. IM appears to be a growing specialty in medicine that has a financially 
promising future, thus investigating the efficacy of integrative therapies is important.  
XII. Purpose of Dissertation 
The main purpose of this dissertation was to characterize nutrition-based therapies for 
FBDs used in an IM clinic at an academic medical center. Furthermore, I wanted to determine 
the efficacy of these therapies. A final goal of the study was to determine whether FBD patients 
seen in an IM clinic present with any nutritional deficiencies.  
My central hypothesis was that persons with FBDs who visit The University of Kansas 
(KU) IM will receive nutrition-based interventions to address FBD, and most patients will report 
improved symptomatology from these nutrition-related interventions. I tested my central 
hypothesis by pursuing the following specific aims and hypotheses: 
XIII. Specific Aims and Hypotheses 
Specific Aim 1: To determine and describe the types of interventions used for patients with 
FBDs at KU IM.   
Specific Aim 2: To determine the change in digestive tract symptom score (based on the 
Medical Symptoms Questionnaire (MSQ)) from baseline to post-intervention follow up in 
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patients with FBDs treated at KU IM. Hypothesis: I hypothesize that patients will report a 
significantly lower MSQ digestive tract symptom score from baseline to follow up.  
Specific Aim 3: To determine whether there are common micronutrient deficiencies among 
patients with FBDs who present at an IM clinic for care, and specifically, if there are deficiencies 
of zinc, copper, magnesium, vitamin B12, vitamin B6, or vitamin D. 
XIV. Justification and Significance 
FBDs are common in the US and globally [14 61]. Although overall prevalence of FBDs is 
unknown, about 11% of the world population is diagnosed with IBS (the most common FBD) 
[170]. There is growing interest in nutrition-related interventions and research on FBDs. For two 
main reasons, KU IM is an ideal population to test these hypotheses: 1) KU IM sees many clients 
with FBD diagnoses (often without relief following conventional treatment) and 2) KU IM is a 

















I. Data Collection Overview  
To investigate the efficacy of nutrition-based interventions for FBDs, I conducted a retrospective 
chart review. I screened patient charts beginning May 1, 2016 and moved backward in time. 
II. Study Population and Chart Selection 
I reviewed patient charts from the Integrative Medicine clinic at The University of 
Kansas Medical Center (KU Integrative Medicine). I randomly selected charts from KU 
Integrative Medicine beginning May 1, 2016 and moved backward in time.  
 Charts were reviewed for study inclusion if the patient fit study criteria (See Table 5). For 
aims 1 and 3, all 74 patients who fit study criteria were included in the final analysis to answer 
the research questions. For aim 2, 17 charts were omitted from the original 74, leaving 57 charts 
in the final analysis. The 17 additional charts were omitted because: 1) patients filled out the 
second MSQ at the intervention visit (n=6), 2) patients completed the first MSQ after the 
intervention visit (n=3); 3) a patient left the 2nd MSQ blank (n=1); 4) the time between the first 
and second MSQs was longer than 18 months (n=3); 5) a patient did not complete a post-
intervention MSQ, or 6) patients completed the MSQ incorrectly (n=3).  
III. Sample size determination 
The number of charts reviewed was determined based on a power calculation. I planned 
to review at least 40 charts of patients with IBS to reach statistical power for Aim 2. Using a 
two-sided paired t-test, this study has 80% power at an alpha of 0.05 to detect a moderate effect 
size of 0.45 (Cohen’s d).  
Based on these numbers, I collected data for aims 1 and 3. 
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IV. Inclusion and Exclusion Criteria 
Patients’ charts were selected for the retrospective chart review (or excluded from the study) 
based on the following inclusion and exclusion criteria (Table 5).  
Table 5: Study inclusion and exclusion criteria. 
 
V. Study Variables 
A. Measuring Symptom Change: The Medical Symptoms Questionnaire (MSQ) 
The MSQ is a clinical and research tool [171-173], organized by body systems (e.g. head, 
nose, digestive tract, emotions, etc.), and is used to measure patient-reported symptoms. See 
Appendix A for the MSQ. The MSQ asks patients to rate symptoms on a scale from 0-4 (0 
means the patient never or almost never has the symptom, and 4 means the patient experiences 
Inclusion Criteria Exclusion Criteria 
• 21-89 years of age  
• Diagnosed with “functional bowel 
disorder” and/or “irritable bowel 
syndrome” and/or other functional 
digestive disorder  
• Attended 3 or more appointments at 
KU Integrative Medicine with a 
“provider” (medical doctor, advanced 
practice registered nurse, physician 
assistant or registered dietitian)  
• Followed up within 18 months of 
intervention consultation (applicable to 
aim 2) 
• Third follow up occurred on or before 
May 1, 2016 
• Completed at least 2 Medical 
Symptoms Questionnaires (baseline 
and follow up after intervention) 
(applicable to aim 2) 
• Only consultation at KU Medical 
Center was with a Registered Dietitian 
(likely no medical diagnoses in the 
chart) 
• Attended fewer than 3 appointments 
• Follow up occurred longer than 18 
months after intervention consultation 
(applicable to aim 2) 
• Completed fewer than 2 Medical 
Symptoms Questionnaires (applicable 
to aim 2) 
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the symptom frequently and the symptom’s effect is severe). Although the MSQ has not been 
validated, other investigators have used it to detect a change in symptoms over time [172 173]. 
Lerman and colleagues [172] used the MSQ joint/muscle sub-category to detect change over 
time in joint pain and arthritis. The digestive tract symptoms on the MSQ include diarrhea, 
constipation, bloating, and intestinal pain, which are appropriate symptoms to assess in patients 
with FBDs.  
B. Measuring Micronutrients 
 Micronutrient levels were measured via serum or plasma testing by a commercial 
laboratory using validated procedures. Practitioners gave patients orders to have their blood 
drawn and analyzed at one of several different laboratories (e.g. Quest Diagnostics, Lab Corp, 
KU Medical Center, or others).  
VI. Analysis of Data  
Quantitative data was analyzed using statistical software.  
Analysis of Specific Aim 1: Aim 1 is a descriptive aim. I used descriptive statistics for the 
various treatments used to treat FBDs at KU Integrative Medicine. 
Analysis of Specific Aim 2: I used a paired 2-sample t-test to compare the baseline and 
post-treatment MSQ scores for the IBS patients’ digestive tract sub-scores. For non-parametric 
data, I used a Wilcoxon Signed Rank Test to analyze the Functional Bloating, Constipation and 
Diarrhea patients’ digestive tract sub-scores.  
Analysis of Specific Aim 3: Aim 3 is a descriptive aim. I used descriptive statistics to 
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 Background Functional bowel disorders (FBDs), like irritable bowel syndrome (IBS) 
and others, are often difficult to treat because they have complex pathophysiology and do not 
necessarily have a physical abnormality. Patients often seek alternative options for treatment 
when they experience medication side effects or no relief. Integrative Medicine (IM) is an ideal 
specialty to investigate these alternative interventions for IBS and other FBDs. Aim The purpose 
of this study was to characterize IM interventions for FBDs in an IM clinic at an academic 
medical center. Methods We performed a retrospective chart review to describe IM 
interventions for FBDs at an IM clinic in an academic medical center. Results Most patients 
were told to take dietary supplements (94.6%) and next most often were told to follow an 
elimination diet (87.8%). Patients told to follow an elimination diet were most often suggested to 
avoid gluten (96.9%) or dairy (80%). Conclusions IM providers at this academic medical center 
frequently recommended lifestyle-based (diet, exercise) interventions for patients diagnosed with 
FBDs. Gluten and dairy were the two most commonly eliminated food categories. IM providers 
at this clinic have an opportunity to employ additional evidence-based interventions to their 
patient interventions, including peppermint oil, herbs, and others. Our results may contribute to a 
protocol that could be used in this and other IM clinics for treatment of FBDs.  
Introduction  
Functional bowel disorders (FBDs) are often difficult to treat, as they have complex 
pathophysiology and do not necessarily have a physical abnormality. FBDs are diagnosed based 
on patient-reported symptoms. Patients report gastrointestinal (GI) symptoms and are 
subsequently tested for several possible physical abnormalities via colonoscopy, endoscopy, 
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celiac disease testing, abdominal ultrasound among other available tests, but test results are 
negative. Next, clinicians use patient-reported symptoms to determine whether a patient can be 
diagnosed with an FBD. In other words, a patient is often diagnosed with an FBD after physical 
evidence of disease has been ruled out. Although patients with FBDs do not necessarily live 
shorter lives (no increased mortality), FBDs do, however, decrease patients’ quality of life, affect 
work attendance and impact patients’ participation in normally pleasurable activities [1].  
There are many FBDs; Irritable bowel syndrome (IBS) is the most common FBD, and 
IBS has been described by De Giorgio and colleagues [174] as the “the prototype of all 
functional bowel disorders” due to its negative effect on quality of life and wide prevalence. IBS 
encompasses different subtypes: diarrhea-dominant IBS (IBS-D), constipation-dominant (IBS-
C), IBS with symptoms that alternate between constipation and diarrhea, called mixed-type (IBS-
M), and unspecified IBS (IBS-U). IBS is defined by chronic GI pain with change in stool form 
and/or frequency. If a patient experiences diarrhea, constipation or bloating without pain and 
without other organic disease, these patients are diagnosed with other functional bowel disorders 
(e.g. functional diarrhea (FD), functional constipation (FC), or functional bloating (FB)) [14].  
 Although the direct and indirect costs per patient of FBDs vary [8], the overall (direct and 
indirect) annual cost of FBDs in the US are upwards of $26 billion US dollars [9]. Not only do 
FBDs have a physical and financial impact on patients, they cost healthcare providers more time 
than patients with other GI conditions [6]. Interestingly, IBS experts more accurately diagnose 
IBS than non-expert practitioners, and experts spend less money on testing than non-experts to 
reach an accurate diagnosis ($297 vs. $658) [10]. Contrary to common belief, IBS experts do not 
consider IBS a “diagnosis of exclusion” [10].  
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 Treatment of FBDs depends on each patient’s specific symptoms [14]. If a patient has 
loose stools, the physician might prescribe an anticholinergic, antispasmodic, or anti-diarrheal 
medication. If the patient reports constipation, the physician may prescribe polyethylene glycol 
(PEG) or fiber. Some physicians even prescribe antidepressants to patients with FBDs, especially 
when a patient reports pain. Non-medical treatments include dietary recommendations, 
nutritional supplements, and psychotherapy [35]. Patients often turn to these “alternative” 
therapies if they want to approach their symptoms without pharmaceuticals or if they experience 
negative medication side effects [175]. See Table 6 for a summary of IBS interventions. 
Interventions for IBS vary by the predominant symptom. For example, patients with IBS-C are 
often recommended to take fiber supplements while patients with IBS-D can sometimes have 
exacerbation of symptoms with high amounts of added fiber [176]. 
Since primary care physicians and gastroenterologists have limited time to spend with 
patients on nutrition or psychological-based counseling, there is an opportunity for other 
healthcare providers to offer alternative treatments. Integrative medicine (IM) is a medical 
specialty that emphasizes nutrition-based therapies [164]. The IM clinic at The University of 
Kansas (KU) – an academic medical center – specializes in nutrition-based treatments and often 
sees patients with gastrointestinal complaints. Thus, patients from KU IM were the ideal 
population to study alternative treatments for FBDs. This study aimed to describe the types of 
interventions for FBDs used by practitioners at an integrative medicine clinic at an academic 






Table 6: Conventional and Integrative interventions for IBS. 
 Conventional Therapies* 
Integrative Therapies 








• Antibiotics (e.g. Rifaximin) 
• 5-HT3 antagonist (e.g. 
Alosetron) 
• Antidepressants (TCAs and 
SSRIs) 
• Antispasmodics 
• Laxatives (e.g. PEG) 
Mind-Body Interventions 
• Cognitive Behavioral 
Therapy 
• Gut-directed hypnotherapy 
Biologic and Nutritional 
Therapies 
• Elimination diets 
• Probiotics 
Dietary Supplements 
• Prebiotics and synbiotics 
• Fiber 






• Cromolyn sodium 
IBS-D 
• Opioid agonists 
• Diet (Gluten-free, Low 
FODMAP) 
• Bile salt sequestrants 
• Probiotics 
• Antibiotics 
• 5-HT3 antagonists 
• Mixed opioid 
agonists/antagonists 




• Chloride channel activators 
• Guanylate Cyclase C agonists 
(e.g. Linaclotide) 
• Lubiprostone 




• Smooth muscle antispasmodics 
• Peppermint oil 
• Tricyclic antidepressants 
• SSRIs 
• Chloride channel activators 
• Guanylate cyclase C agonists 
• 5-HT3 antagonists 
Primarily in pediatrics:  
hypnosis, yoga, acupuncture, 
massage, guided imagery, 
biofeedback, and distraction. 
*Modified from Lacy 2016 and Chang 2014 [14 177] 
**IBS interventions based on reviews by Wald & Rakel 2008 and Mullin 2014 [33 178], 
Abdominal pain interventions based on review by Friedrichsdorf 2016 [179]. 
Methods 
This study was conducted at KU IM as a retrospective chart review to determine how IM 
practitioners treat FBDs. Patients’ charts were selected for the study based on the following 
inclusion and exclusion criteria (Table 7).  
Patients 
A total of 547 charts were screened for fit to study criteria. Patient charts were identified 
for inclusion in the study if the patient was diagnosed with any Functional Bowel Disorder (e.g. 
IBS, Functional Bowel Abnormality, Functional Constipation, etc.). Seventy-five patients fit 
study criteria (see Table 7 for inclusion/exclusion criteria). Based on initial diagnosis by 
integrative medicine practitioners (MD, PA, APRN), patients were given 1 of 10 different 
diagnoses (see Table 8). The initial 10 diagnoses included: IBS, IBS-D, IBS-C, IBS-M, FBD, 
Functional Disorder of Intestine, FBD-C, Irritable Bowel, Functional Bowel Abnormality, and 
Functional Diarrhea. A board-certified gastroenterologist reviewed all records and determined 
the final diagnosis based on the Rome IV diagnostic criteria, physician documentation, and 
patient-reported symptoms. The criteria for diagnosis were presence or absence of pain and 
presence or absence of constipation, diarrhea, or bloating. The 6 final diagnoses included IBS-C, 
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IBS-D, IBS-M, Functional Diarrhea (FD), Functional Constipation (FC), and Functional 
Bloating (FB) (See Table 9 below). Table 10 shows the patients’ predominant symptom pattern 
irrespective of pain, and thus can be characterized with the following symptom patterns: 1) 
constipation, 2) diarrhea, 3) alternating or mixed symptomatology or 4) bloating. One of the 
patients who was initially identified for study inclusion was determined not to fit Rome Criteria 
IV for any FBD. That patient was excluded from the study. The remaining 74 patients were 
included for final study analysis.  







Inclusion Criteria Exclusion Criteria 
• 21-89 years of age  
• Diagnosed with “functional bowel 
disorder” and/or “irritable bowel 
syndrome” and/or “functional 
dyspepsia” 
• Has attended 3 or more appointments at 
KU IM with a “provider” (medical 
doctor, advanced practice registered 
nurse, physician assistant or registered 
dietitian)  
• Third follow up on or before May 1, 
2016 
• Only consultation at KU Medical 
Center was with a Registered Dietitian 
(likely no medical diagnoses in the 
chart) 
• Patient has attended fewer than 3 
appointments 
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Table 8: Diagnoses in patient’s medical record 






Functional disorder of intestine 13 
FBD-C 5 
Irritable bowel 1 
Functional bowel abnormality 1 
Functional diarrhea 1 
Total Diagnoses 82* 
* The total number of patient diagnoses is greater than 74 because some patients were given 
multiple FBD diagnoses. 
Table 9: Diagnoses by Gastroenterologist 




Functional Constipation 11 
Functional Bloating 4 
Functional Diarrhea 3 
Total Diagnoses 74 
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Table 10: Symptom pattern irrespective of pain 
Predominant symptom Number of patients 
Constipation 34 
Diarrhea 22 




Retrospective Chart Review 
This study was a retrospective chart review to describe interventions for patients with 
FBDs at an IM clinic at an academic medical center (KU IM). A patient chart was included in 
the study if he or she was diagnosed with a FBD. Once a patient was selected for study inclusion, 
the patient’s chart was reviewed to characterize the interventions recommended to the patient. 
The “intervention appointment” was defined as the appointment that followed the initial or 
“baseline” appointment when the practitioner reviews lab results with the patient and makes a 
treatment plan or “intervention”. The intervention might include recommendations from a 
diagnosing healthcare provider (provider) such as a medical doctor (MD), a nurse practitioner 
(APRN), or a physician assistant (PA) and/or a registered dietitian-nutritionist (RDN). Both the 
provider and RDN interventions were included if the appointments were within 6 months of each 
other.  
The intervention was recorded, reviewed and coded to determine if the provider had 
recommended that the patient follow one of several interventions. Initially, 38 total interventions 
were identified, and subsequently collapsed into 9 intervention categories. The 9 categories 
included 1) elimination diet, 2) vitamin or mineral supplementation, 3) magnesium 
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supplementation, 4) GI-related supplement (including probiotic, digestive enzyme, betaine 
hydrochloric acid), 5) fermented foods, 6) water (hydration), 7) non-diet lifestyle modification 
(physical activity, stress management), 8) referral (non-RDN), and 9) GI-related prescription. 
Table 11 shows a summary and descriptions of the 9 categories of IM interventions for FBDs 
assessed in this study.  
After the 9 IM intervention categories were defined, each patient’s intervention 
appointment(s) were tallied for the intervention(s) he or she received. Once all charts were 
reviewed, totals for each of the 9 categories of integrative intervention were compiled to 
determine which interventions were most- and least-often recommended to IM patients.  
Table 11: Summary and descriptions of the possible integrative interventions for FBDs used in 
this study population. IM: integrative medicine; RDN: registered dietitian-nutritionist; MD: 
medical doctor; APRN: advance practice registered nurse; PA: physician assistant.  
IM intervention categories for treatment 
of Functional Bowel Disorders Description of Intervention 
Elimination Diet 
MD, APRN, PA or RDN recommended 
that a patient eliminate a certain food or 
food group or to see a dietitian for this 
therapy. Example: recommend that a 
patient eliminate gluten, casein and eggs 
for a certain number or weeks to determine 
if symptoms resolve or improve. 
Vitamin or mineral supplementation 
MD, APRN, PA or RDN recommended 
that a patient start or continue taking any 
kind of vitamin or mineral supplement 
Magnesium supplementation 
MD, APRN, PA or RDN recommended 
that a patient start or continue taking 
magnesium. 
GI-related supplementation (probiotic, 
digestive enzyme, betaine hydrochloric 
acid) 
MD, APRN, PA or RDN recommended 
that a patient start or continue taking a 
probiotic, digestive enzyme or betaine 
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hydrochloric acid (betaine HCl) 
Fermented foods 
MD, APRN, PA or RDN recommended 
that a patient consume fermented foods 
(example: sauerkraut). 
Water (hydration) MD, APRN, PA or RDN recommended that a patient increase water intake.  
Lifestyle modification (non-diet: physical 
activity, exercise, stress management) 
MD, APRN, PA or RDN recommended 
that a patient engage in physical activity or 
practice stress management 
Referral (not including referral to RDN) 
Referrals included any healthcare referral 
that was not a referral to an RDN (since 
RDN interventions were included in the 
integrative intervention data collection). 




Sixty-three (85.1%) of the patients were women. The mean age of patients at their 
baseline visit to KU IM was 50.8 years old (std. dev. 12.8 years) with a range between 22 and 80 
years. The main reason patients reported coming to KU IM (either reported by the patient in 
paperwork or provider in the medical note) was for GI-related complaints in 33 of the 74 
(44.6%) of patients in this study. The next most common reason for visiting was for pain-related 
issues (27%), hormone problems (24.3%), fatigue or energy issues (18.9%) and overall health, 




Interventions at Clinic Appointments 
The most common intervention recommended by IM providers was to follow an 
elimination diet. The recommendation was made to patients at 103 (78.6%) of the 131 total 
patient appointments. The second most common recommendation was vitamin or mineral 
supplements, recommended at 83 of 131 patient appointments (63.4%). Providers or RDNs 
recommended that patients take GI-related supplements (digestive enzymes, probiotics and/or 
betaine HCl) 48.9% of the time. A provider or RDN suggested magnesium supplementation at 
45.0% of patient appointments. The next most common interventions for FBD patients were non-
diet lifestyle interventions (32.1% of appointments), water drinking (29.0%), non-dietary referral 
(25.2%), and consumption of fermented foods (16.0%). GI-related medications were prescribed 
at 32.9% of appointments (24 out of 73 patient appointments with providers since RDNs are 
unable to prescribe medications.). See Table 12 for a summary of intervention data.  
Since patients of KU IM seek consultations for more issues than gastrointestinal 
complaints, the interventions often involved recommendations that were not directly related to 
the GI tract. For example, some providers suggested that patients follow a detoxification 
program, eat organic foods, drink filtered water or take hormones. These interventions were 
collected but not included in the summary of interventions for FBD in this study since they were 







Table 12: Frequency of recommended interventions to patients with FBDs. 
Intervention Frequency of recommendations 
(out of 131 total patient visits) 
n (%) 
Elimination diet (% of 131 total patient visits) 103 (78.6%) 
Vitamin and/or mineral supplementation (% of 131 
total patient visits) 
83 (63.4%) 
GI-related supplementation (% of 131 total patient 
visits) 
64 (48.9%) 
Magnesium supplementation (% of 131 total patient 
visits) 
59 (45.0%) 
Lifestyle modification (non-diet) (% of 131 total 
patient visits) 
42 (32.1%) 
GI-related prescription (of 73 total patient visits) 24 (32.9%) 
Water (hydration) (% of 131 total patient visits) 38 (29.0%) 
Referral (not including referral to RDN) (% of 131 
total patient visits) 
33 (25.2%) 
Fermented foods (% of 131 total patient visits) 21 (16%) 
 
Interventions by FBD Diagnosis 
Interventions for each diagnostic subtype are reported in Table 13 and include 
recommendations made by providers (MD, APRN, PA) and/or RDN. When analyzed by patients 
receiving any FBD diagnosis (n=74), the most common intervention was vitamin or mineral 
supplementation (94.6% of study patients) with the next most common intervention being an 
elimination diet (87.8% of patients) followed by magnesium and GI supplements (74.3% each), 
water intake (44.6%), non-diet lifestyle interventions and non-dietary referrals (43.2% each), and 
least-often recommended were prescription medications (37.7%).  
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Table 13: Frequency of therapies recommended for all patients with FBDs (“overall”) in the 






























































































































































Frequency of recommendation of various types of elimination diets.  
Practitioners at KU IM recommended that 65 of the 74 total patients (87.8%) follow an 
elimination diet. Of these 65 patients told to follow an elimination diet, 59 patients (90.8%) were 
instructed to eliminate gluten and/or wheat, 52 (80%) to eliminate dairy and/or casein, 28 
(43.1%) were told to avoid eggs, and 22 (33.9%) were told to avoid soy. KU IM practitioners 
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suggested that 25 patients (38.5%) follow a grain-free diet (e.g. wheat, rye, barley, corn, oats, 
rice, etc.). If you combine the patients who were told to avoid gluten and/or grains (which would 
also include gluten), then 63 patients (96.9%) were told to avoid gluten (whether directly or via 
grain elimination). In other words, 96.9% of patients who were told to follow an elimination diet 
were instructed to eliminate gluten.  
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Table 14: Elimination diet recommendations by diagnosis and the specific food(s) providers 



































































































































FBD, functional bowel disorder; IBS, irritable bowel syndrome; IBS-C, constipation-dominant 
IBS; IBS-D, diarrhea-dominant IBS; IBS-M, mixed type IBS; FC, functional constipation; FB, 
functional bloating; FD, functional diarrhea. 
Discussion 
IM “care plans” (referred to here as “interventions” or “therapies”) have been described 
by the 2012 Bravewell report (“Integrative Medicine in America: How Integrative Medicine Is 
Being Practiced in Clinical Centers Across the United States”) [164]. The Bravewell report was a 
study of 29 IM clinical centers across the U.S. and described IM use in the U.S. Per the 
Bravewell report, lifestyle interventions include recommendations for diet, exercise, provision of 
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clean air and water, eliminating toxins from home and work environments, and stress reduction. 
Sixty-two percent of US IM centers include lifestyle interventions in their care plans. Based on 
our study, 91.9% (68 of 74) patient appointments at KU IM resulted in recommendations for 
lifestyle interventions. Based on my findings, I created a KU Integrative Medicine Care 
Algorithm (see Appendix B). 
 Although others have described IM therapies for gastrointestinal disease (including IBS), 
diet-related interventions outside of supplementation (peppermint oil, ginger, probiotics and 
others) have seldom been described [175]. Thus, this study provides evidence for the use of 
therapeutic diets (specifically elimination diets) to address FBDs.  
 Our study demonstrates the frequent use of dietary and nutrition-based interventions by 
IM providers and RDNs at an academic medical center. Previous evidence by Zar [180] and 
Drisko [91] suggest that elimination diets based on IgG food sensitivity testing are effective to 
alleviate GI symptomatology and improve quality of life. A small study (n=21) of patients with 
IBS and migraine had significantly lower symptoms of both conditions following elimination 
diet [181].  
This academic IM clinic less frequently used some of the more cited FBD interventions 
like peppermint oil, melatonin, and/or iberogast [33]. More frequently, KU IM practitioners 
recommended probiotics to patients. Despite efficacy of some integrative therapies (i.e. 
peppermint oil, fiber supplements, mind-body therapies (e.g. CBT, prebiotics, l-glutamine, zinc, 
melatonin, iberogast, cromolyn) [33], some available therapies were not recommended to 
patients in this study population. Mindfulness is another approach that, when taught to patients, 
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may lessen the severity of IBS symptoms [182]. This suggests not all evidence-based options 
available to providers at this academic IM clinic were utilized in recommendations. 
 The interventions described in this study are a glimpse into the total care process at this 
academic medical center IM clinic. Since IM takes a holistic approach to health, there are often 
several visits for each client, at which several therapy recommendations are made. Along those 
lines, interventions in this study may seem falsely comprehensive since we included 
interventions from both RDNs and other providers’ (MD, PA, APRN).  
The conclusions from this study are limited to a single IM clinic. Several different 
approaches to FBDs are available, and each IM clinic may practice differently [33], especially 
when IM practices have different provider types; if a clinic did not have RDNs, we might assume 
that dietary interventions would be used less frequently. Interventions from this one clinic may 
not be representative of other academic medical center IM clinics.  
 Per the Bravewell Collaborative, the health conditions for which IM treatments are the 
most clinically successful, include, in descending order: chronic pain (75%), gastrointestinal 
disorders (59%), depression/anxiety (55%), cancer (52%) and stress (52%). Thus, based on the 
effectiveness of IM treatments of gastrointestinal disorders, the patients from this study who 
sought help for GI complaints were likely to find the interventions were effective. A practical 
next-step to investigate would be to measure the efficacy of these interventions.  
Conclusions & Future Directions 
 IM providers at this academic medical center most often recommended that FBD patients 
follow an elimination diet and/or take dietary supplements. The most common food category 
recommended to eliminate was gluten, followed by dairy. There is an opportunity for IM 
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providers to consider additional approaches, like peppermint oil or other evidence-based, 
alterative approaches to FBDs. Providers in this clinic widely suggested lifestyle-based 
interventions to patients, which are low-risk approaches to address FBD symptoms. A logical 
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 Background Functional bowel disorders (FBDs), including irritable bowel syndrome 
(IBS) and others, are complex conditions that, as a result, are difficult to treat. Alternatives to 
medical interventions are ideal because IBS patients are a burden on physicians’ time and 
healthcare spending. Aim The goal of this study was to determine the efficacy of alternative, 
lifestyle interventions for patients with FBDs. Methods Since integrative medicine (IM) 
specializes in alternative and lifestyle interventions, we performed a retrospective chart review in 
an IM clinic at an academic medical center to determine whether patients with FBDs had 
improvement in symptoms following IM interventions. We measured improvement using a 
medical symptoms questionnaire (MSQ) that is regularly used to measure symptom change in 
IM clinics. Results Digestive tract symptoms measured by the MSQ improved significantly in 
patients with FBDs following IM intervention. The mean pre-intervention MSQ Digestive Tract 
subtotal was 10.2 (s.d. 5.4) and the mean post-intervention score was 7.2 (s.d. 5.2). For FBD 
patients, the average digestive tract symptom score change was -3.0 (p<0.0000001). The 
majority of patients received nutrition-related interventions (specifically dietary supplements and 
elimination diet recommendations). Conclusions Patients in an IM clinic had improved digestive 
tract symptoms scores following IM intervention. Nutrition-based interventions were the primary 
intervention recommended by IM providers. Thus, nutrition-based interventions may be a viable 
intervention for primary care physicians and gastroenterologists who lack time for FBD patients. 
These providers can refer patients to Registered Dietitian-Nutritionists (RDNs) skilled in 




 Functional bowel disorders (FBDs) are a group of conditions that includes irritable bowel 
syndrome (IBS), functional bloating (FB), diarrhea (FD), functional constipation (FC), and 
unspecified functional bowel disorders (FBD-U) [61]. FBDs are not life-threatening conditions, 
but they negatively impact patients’ quality of life [62]. FBDs are diagnosed based on patient-
reported gastrointestinal (GI) symptoms despite a lack of physically identifiable etiology. IBS is 
the most common FBD. Patients with IBS report pain and their symptoms are related to 
defecation or a change in bowel habits. IBS symptoms are characterized by either constipation-
dominance (IBS-C), diarrhea-dominance (IBS-D), mixed symptomatology (IBS-M), or are 
unclassified (IBS-U) [14]. IBS has both complex pathophysiology (also, not fully understood) 
and treatment [63]. Less common FBDs are FB, FD, and FC; these patients experience similar 
changes in bowel habits (constipation, diarrhea) or bloating but do not report pain (unlike IBS 
patients). 
Internal medicine and family physicians refer about one third of their IBS patients to 
gastroenterology specialists [6]. Gastroenterologists report these patients are less ill than other GI 
patients but that IBS patients require more of their time [6], possibly reflecting some of the 
psychosocial effects of IBS. Thus, IBS patients pose a time burden on physicians who need to 
care for more critically ill patients, and alternative forms of care may be warranted. 
Horrigan and colleagues [164] describe IM an approach to healthcare that “puts the 
patient at the center  and addresses          
and environmental influences that affect a person’s health” and combines therapies from 
conventional medicine and complementary and alternative medicine (CAM) [163]. The 
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Academic Consortium for Integrative Medicine and Health states that “Integrative medicine and 
health reaffirms the importance of the relationship between practitioner and patient, focuses on 
the whole person, is informed by evidence, and makes use of all appropriate therapeutic and 
lifestyle approaches, healthcare professionals and disciplines to achieve optimal health and 
healing” [165]. One challenge to doctors treating patients with IBS is the importance of the 
therapeutic relationship between practitioner and patient [183], which is increasingly difficult to 
develop within the limited time providers have with patients. IM practitioners have significant 
time with patients to do clinical assessment and rapport-building, and IM healthcare providers 
can suggest and implement lifestyle interventions for FBD patients [166]. 
Most patients with IBS report stronger confidence that lifestyle recommendations would 
help them, but patients adhere more to medication recommendations [11]. Many IM 
interventions are based on lifestyle changes (e.g. diet, exercise, sleep), so an IM clinic is an 
appropriate population to study the impact of dietary interventions on persons with FBDs. 
Patients in an IM setting may be more willing to make lifestyle changes since these patients seek 
this additional healthcare and often pay out-of-pocket for their care. Thus, the IM clinic at an 
academic medical center (The University of Kansas (KU) Integrative Medicine) was the ideal 
setting to study the efficacy of lifestyle interventions in patients with FBDs. The aim of this 
study was to determine whether interventions for FBD patients at an IM clinic at an academic 







This was a retrospective chart review including 74 patients from an integrative medicine 
clinic at an academic medical center. Inclusion and exclusion criteria are found in Table 15. 
Patient charts were reviewed starting with May 1, 2016 and moving back in time until 85 
subjects had been identified. Patients were included in the study if they were between the ages of 
21 and 89 years old and diagnosed with a FBD (e.g. IBS, functional disorder of intestine, 
functional diarrhea, etc.). The patient must have attended at least 3 appointments at KU IM with 
a MD, APRN, PA or RDN. Finally, the time between initial completion of the medical 
symptoms questionnaire (MSQ) and follow up MSQ could not be longer than 18 months. 
Patients must have completed at least 2 MSQs to be included in the study.  
Seventy-four patients fit study criteria, and 57 were included in the final analysis. 
Seventeen patients were excluded from the study for various reasons. The reasons included: 1) 
the patient’s second MSQ completed at intervention visit, 2) the patient’s first MSQ was 
completed after intervention visit, 3) the patient’s second MSQ was blank or unfinished, and 
other reasons (see Table 16).  
Symptom Measurement 
To measure the effectiveness of the intervention, a symptom measurement tool was 
needed. At KU IM, patients are asked to complete a Medical Symptoms Questionnaire (MSQ) 
for each clinic visit to measure patient-reported symptoms. The MSQ is a clinical and research 
tool [171-173], organized by body system (e.g. head, nose, digestive tract, energy, emotions, 
etc.), and the MSQ is used to measure patient-reported symptoms. The MSQ asks patients to rate 
 58 
symptoms on a scale from 0-4 (0 means the patient never or almost never has the symptom, and 
4 means the patient experiences the symptom frequently and the symptom’s effect is severe). 
Although the MSQ has not been validated, it has been used in other research to measure change 
in patient-reported symptoms over time [172 173]. Lerman and colleagues [172] used the MSQ 
to detect change over time in the joint/muscle sub-category to measure symptom change related 
to joint pain and arthritis. We used the MSQ to measure the change in digestive tract symptom 
severity from baseline to follow-up. 
Table 15: Study inclusion and exclusion criteria. 
Inclusion Criteria Exclusion Criteria 
• 21-89 years of age  
• Diagnosed with “functional bowel 
disorder” and/or “irritable bowel 
syndrome” and/or “functional 
dyspepsia” 
• Attended 3 or more appointments at 
KU Integrative Medicine with a 
“provider” (medical doctor, 
advanced practice registered nurse, 
physician assistant or registered 
dietitian)  
• Followed up within 18 months of 
intervention consultation 
• Third follow up on or before May 
1, 2016 
• Completed at least 2 Medical 
Symptoms Questionnaires (baseline 
and follow up after intervention) 
• Only consultation at KU Medical 
Center was with a Registered 
Dietitian (likely no medical 
diagnoses in the chart) 
• Attended fewer than 3 
appointments 
• Follow up longer than 18 months 
after intervention consultation 
• Patient completed fewer than 2 






Table 16: Rationale for excluding patient charts from final analysis* 
Rationale 
1. Patient’s 2nd MSQ completed at intervention visit (n=6) 
2. Patient’s 1st MSQ was completed after intervention visit (n=3) 
3. Patient’s 2nd MSQ was blank/unfinished (n=1) 
4. Time between MSQs was greater than 18 months (n=3) 
5. No post-intervention MSQ completed (n=1) 
6. MSQs not completed correctly (n=3) 
 
*Total patient charts excluded from study (n=17) 
Statistical Analysis 
To determine the efficacy of IM treatment of FBDs, we compared the change in baseline 
MSQ digestive tract scores to post-intervention MSQ digestive tract scores. For normal data (IBS 
patient data), I performed a paired t-test to determine whether the difference between the 
baseline and post-intervention MSQ Digestive Tract scores were significantly different. For non-
normal data (FB, FC, FD patients), I used a Wilcoxon Signed-Rank Test to determine whether 
the means for the pre- and post-intervention MSQ digestive scores were different.  
RESULTS 
 Fifty-seven patients fit study criteria with an average age of 49.8 ± 13.7 years (range 22-
80 years), and 84.2% (n=48) patients were women. Out of the 57 patients who fit study criteria 
and correctly completed at least 2 MSQs (pre-intervention and post-intervention), 43 (75.4%) of 
patients had improved digestive tract symptoms scores from baseline to post-intervention, 9 
(15.8%) of the patient’s symptoms worsened, and 5 (8.8%) patient’s digestive tract symptoms 
remained unchanged.  
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After testing the data for normality (data normally distributed), we performed a paired t-
test. The mean baseline digestive tract score was 10.2 (standard deviation 5.4) and the mean 
post-intervention score was 7.2 (standard deviation 5.2) (see Table 17). For all FBD patients, the 
average digestive tract symptom score decreased 3.0 points (p<0.0000001). See Figure 5 for 
graphical representation of overall average digestive tract MSQ score change for all FBD 
patients.  
For patients with IBS (all sub-categories), the mean change in MSQ score was -3.66 
(s.d.=4.0), and the change in MSQ scores for all IBS patients from pre- and post-intervention 
was statistically significant (p<0.000001) from a mean of 11.4 (s.d.=5.2) to 7.8 (s.d.=5.1). See 
Figure 6. Also, see Table 18 for p-values by category: 1) diagnosis, 2) IBS, and 3) dominant 
symptom. For symptom change by IBS sub-category, symptom improvement was statistically 
significant for patients with IBS-C (p=0.005), IBS-D (p=0.0004), and IBS-M (p=0.02), while 
symptom change (per MSQ score) for the other FBDs were not statistically significant. See 
Figure 9 (IBS-C), Figure 10 (IBS-D), and Figure 11 (IBS-M) for graphical representation of 
MSQ symptom score change. See Figures 12-14 for change in MSQ GI scores for FB, FD, FC.  
Table 17: Mean pre- and post-intervention MSQ scores for all FBD pts 
N=57 Pre-Intervention Post-Intervention 
Mean MSQ GI Score 10.2 7.2 
Standard Deviation 5.4 5.2 








Table 18: Statistical probability of symptom change by diagnosis, IBS and symptom 
GI MSQ Score Symptom Change by Diagnosis and Symptom Type 
Diagnosis 
Pre-intervention 
mean GI MSQ  
Post-Intervention 
mean GI MSQ p-value 
FB (n=3) 7.7 ± 5.5 7 ± 9.5 0.75 
FC (n=7) 5 ± 2.8 4.1 ± 2.4 0.33 
FD (n=2) 6 ± 7.1 5 ±7.1 0.50 
All IBS (n=45) 11.4 ± 5.2 7.8 ± 5.1 <0.000001 
IBS-C (n=18) 11.4 ± 4.7 8.3 ± 3.5 0.005 
IBS-D (n=16) 10.7 ± 5.8 6.0 ± 5.9 0.0004 





Diarrhea (n=18) 10.2 ± 5.9 5.9 ± 5.8 0.0003 






Figure 5: Mean pre- and post-intervention MSQ scores for all FBD patients with error bars. 
Mean baseline digestive tract score 10.2 (s.d. 5.4), mean post-intervention score 7.2 (sd 5.2). 
Mean post-intervention MSQ GI score was significantly different than baseline MSQ GI score 
(p<0.0000001). MSQ, medical symptoms questionnaire; GI, gastrointestinal; FBD, functional 
bowel disorder; Pts, patients. 
  
Figure 6: Mean pre- and post-intervention MSQ GI scores for IBS patients with error bars. Mean 
change in MSQ score was -3.66 (s.d.=4.0), and the change in MSQ scores for all IBS patients 
from pre- and post-intervention was statistically significant (p<0.000001). MSQ, medical 
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Figure 7: Mean pre- and post-intervention MSQ GI scores for patients with diarrhea with error 
bars. Mean change in MSQ score was -4.3 (p=0.0003). MSQ, medical symptoms questionnaire; 
GI, gastrointestinal; Pts, patients.  
 
Figure 8: Mean MSQ GI Score for patients with constipation with error bars. Mean change in 
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Figure 9: Symptom change of IBS-C patients from pre- to post-intervention MSQs (n=18). Red 
= symptoms worsened; Green = symptoms improved; Grey = symptoms did not change. IBS-C, 
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Figure 10: Symptom change of IBS-D patients from pre- to post-intervention MSQs (n=16).  
Red = symptoms worsened; Green = symptoms improved; Grey = symptoms did not change. 
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Figure 11: Symptom change of IBS-M patients from pre- to post-intervention MSQs (n=11).  
Red = symptoms worsened; Green = symptoms improved; Grey = symptoms did not change. 
IBS-M, mixed type (alternating diarrhea and constipation) irritable bowel syndrome. 
 
Figure 12: Symptom change of FB patients from pre- to post-intervention MSQs (n=3).  
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Figure 13: Symptom change of FD patients from pre- to post-intervention MSQs (n=2).  
Green = symptoms improved. 
 
Figure 14: Symptom change of FC patients from pre- to post-intervention MSQs (n=7).  
Red = symptoms worsened; Green = symptoms improved. 
DISCUSSION 
Our study suggests that IM interventions for IBS are effective. Whether IM interventions 
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diagnoses to determine efficacy. One of the most common interventions was an elimination diet. 
The most common foods to be eliminated were (in descending order): gluten and/or grains, 
gluten (alone), dairy or casein, and “other foods” (e.g. beef, pork, caffeine, and others). 
Interestingly, few providers specifically recommended the low FODMAP diet, which is one of 
the more cited dietary interventions for IBS patients. Our data suggest that a less-strict 
elimination diet may be equally effective to the low FODMAP diet in patients with IBS. Others 
who have recommended elimination diets based on IgG food sensitivity testing have found 
benefits for their patients [91 180].   
Since this study was retrospective in nature, we were able to assess the way that KU IM 
treats FBDs without manipulating the methods that practitioners would naturally use in their 
interventions. On the other hand, we were unable to control for variables including dietary 
interventions and completion of MSQs. We also had few patients with non-IBS FBDs (i.e. FB, 
FD, FC) so we cannot draw conclusions from non-IBS patient data.  
Some possible explanations for patients with refractory symptoms include: a) patients 
with early life trauma are known to have increased IBS, b) patients not following recommended 
therapies, c) extensive nature of the interventions may have been overwhelming to the patient 
who ultimately does not follow any recommendations, d) expense of carrying out the 
recommended intervention(s) (although this explanation may be less likely since the patients in 
this clinic pay out-of-pocket for this care), and e) complications of IBS not understood such as 
psychosocial-related symptoms and “rectal perceptual thresholds” [184].   
Spiller [41] suggests that the ideal length of any IBS clinical trial is longer than 12 weeks 
since the placebo effect diminishes at 12 weeks. Our results are compelling because the average 
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time between baseline MSQ and follow up MSQ was 8.75 months (about 35 weeks), which is 
well beyond the point that period of time [41].  
Seventy-six percent of my study patients had improvement in their GI MSQ symptoms 
scores from pre- to post-intervention. The majority (87.8%) of patients received the 
recommendation to follow an elimination diet and an even greater number were told to take a 
vitamin or mineral supplement (94.6%).  
For future research, I would use the IBS Satisfaction with Care (IBS-SAT) [162] 
questionnaire to determine whether patients’ satisfaction differs between conventional and 
integrative IBS care. 
Meta analyses suggest peppermint oil, Chinese herb preparations (specifically 
preparations made in the United States), soluble fiber, probiotics, mind-body therapies (cognitive 
behavioral therapy (CBT) and hypnosis), and variable evidence for acupuncture may be effective 
in treating IBS symptoms [175]. Additionally, a clinical review from the Journal of the American 
Medical Association [183] suggests that holistic, lifestyle interventions are appropriate for 
patients with IBS. Thus, studying the effectiveness of dietary interventions among a population 
of patients in an integrative medicine clinic is appropriate. 
The effectiveness of interventions at KU IM may have been enhanced by defining 
“interventions” to include both recommendations from the diagnosing provider (MD, PA, 
APRN) and the RDN. It would be interesting to see the effect that additional psychological 
counseling would make on the efficacy of the interventions.  
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Our results suggest that integrative medical interventions for FBDs appear to be most 
effective at lowering GI-related symptoms for patients with IBS-D and general diarrhea-
dominant symptoms (including both IBS-D and FD).  
There were several limitations to this study. Patients were primarily Caucasian and able 
to afford healthcare outside of what is covered by Medicare, Medicaid and/or insurance. Thus, 
the results may not be generalizable. Secondly, we did not determine which patients became 
Rome IV criteria-negative after the intervention. Another limitation of the study is the degree to 
which we can be certain that the patients complied with the intervention. However, it would be 
reasonable to assume that the patients in this clinic might be more motivated to follow 
recommendations because they chose to pay for these services out-of-pocket. Another limitation 
is that the MSQ is not a validated tool and it is not specific to IBS patients. For future studies, I 
would suggest using the IBS quality of life (IBS-QOL) [185] to more accurately assess the 
impact on quality of life by these patients’ conditions.  
The low FODMAPs diet and a traditional IBS diet are both effective at alleviating IBS 
symptoms [124]. Although this randomized controlled trial by Böhn and colleagues [124] was 
only a 4-week intervention, this may have been a placebo effect. Our study adds to the evidence 
that dietary interventions can effectively alleviate IBS symptoms in most patients.  
One strength of the study was that KU IM used mostly laboratory testing-based 
interventions to determine the specific elimination diet (instead of a broad spectrum of foods, 
like FODMAP foods). In clinics that do not use laboratory testing or in practitioners who do not 




IM interventions for patients with FBDs appear to be effective, especially among patients 
with IBS. The intervention appears to be most effective among patients with diarrhea-dominant 
symptoms. With this knowledge, primary care physicians and gastroenterologists should 
consider dietary interventions as a first-line therapy for patients with IBS. This would be an 
effective and timesaving approach for these healthcare providers who could refer IBS patients to 
RDNs to implement dietary interventions [6]. Along those lines, an interdisciplinary approach 
with multiple interventions over time may be worthwhile to help patients a) understand and 












MICRONUTRIENT STATUS OF PATIENTS WITH FUNCTIONAL 





Background Patients with functional bowel disorders (FBDs), like patients with irritable 
bowel syndrome (IBS), may change their diets in attempt to alleviate gastrointestinal (GI) 
symptoms. In addition, FBD patients may be less able to absorb nutrients from foods due to fast 
GI motility. These dietary changes and symptoms could increase their risk for micronutrient 
deficiencies. Aim The aim of this study was to determine the status in FBD patients in an 
integrative medicine (IM) clinic of several micronutrients: vitamins B12, B6, D and minerals 
magnesium, zinc and copper. Methods In a retrospective chart review, we collected existing 
micronutrient data on FBD patients using various labs (Quest Lab, Lab Corp, and others). 
Results Patients with FBDs at this IM clinic appeared to have adequate micronutrient status 
except for vitamin D (23% deficient). The majority of patients’ vitamin B6 levels were above the 
reference range, likely due to supplementation. Eighty-five percent of patients were taking 
nutritional supplements at their baseline visit to the IM clinic.  Conclusions Patients with FBDs 
at this IM clinic had adequate micronutrient status and many had elevated vitamin B6 and B12 
levels, likely secondary to supplementation prior to IM consultation.  
INTRODUCTION 
Functional bowel disorders (FBDs) are complex gastrointestinal (GI) conditions that are 
diagnosed based on patient-reported symptoms rather than physical abnormality. FBDs include 
several bowel disorders that negatively impact patients’ quality of life. There are 6 categories of 
FBDs: irritable bowel syndrome (IBS), functional bloating, functional diarrhea, functional 
constipation, unspecified FBDs, and a new category, opioid-induced constipation [14]. IBS is the 
most common FBD and is defined by patient-reported pain and defecation-related symptoms. 
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The pathophysiology of FBDs is not fully understood, so FBDs remain relevant and widely 
studied conditions. Further, patients with FBDs, and especially IBS, may make dietary changes 
(e.g. eliminate trigger foods) since about two thirds of patients report their symptoms are related 
to food intake [187]. Specifically, IBS patients say that carbohydrate and fat-rich foods are the 
most common food-offenders [187]. 
Since IBS patients are likely to alter their diets, they may be vulnerable to micronutrient 
deficiencies. However, little is known about micronutrients status in persons with functional 
bowel disorders (FBDs). Since the primary cause of FBDs is unknown, investigating the 
micronutrient status of patients with FBDs is a reasonable next step to try to further characterize 
this population’s biochemical make up and FBD pathophysiology.  
The body requires micronutrients (vitamins and minerals) to perform countless 
physiological activities. One common evidence-based intervention for IBS is a diet low in 
fermentable carbohydrates (fermentable oligosaccharides, disaccharides, monosaccharides and 
polyols (FODMAP)) or the low FODMAP diet (LFD) [125 186 188]. Although studies in the 
United Kingdom and Norway suggest that patients following an IBS diet are able to meet their 
macro- and micronutrient needs [189 190], elimination of these or other foods (i.e. 
elimination/exclusion diets) may contribute to nutritional deficiencies [191]. Additionally, 
frequent diarrhea, characteristic of diarrhea-dominant IBS (IBS-D) may also put IBS-D patients 
at higher risk for micronutrient deficiencies. Thus, it is reasonable to suspect micronutrient 
deficiencies in these patients since FBDs involve food-triggered symptoms, genetic factors, and 
abnormalities in neurological, immunological, microbiological, and inflammatory aspects of 
health [19 20 74].  
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Although little is known about micronutrient levels in relation to FBDs, new evidence 
suggests the severity of IBS symptoms is inversely related to vitamin D status in British IBS 
patients and that the majority of people with IBS may have vitamin D deficiency [153].  
Magnesium status has not been measured in IBS, but magnesium supplementation may 
effectively alleviate symptoms of IBS [43]. Comorbidities of IBS have characteristics of 
magnesium deficiency, including anxiety [156], chronic headache [157], fibromyalgia [158]. It is 
reasonable to suggest that magnesium deficiency may play a role in patients with both IBS and 
anxiety. In a population of young (18-20 years old) Japanese women dietetic students (n = 3835), 
investigators found that water intake and magnesium intake were independently associated with 
chronic constipation [192]. Mg may be part of the pathophysiology of FBDs, but the mechanism 
of action remains unknown.  
Additionally, magnesium deficiency alters gut microbiota and contributes to anxiety in 
mice [155]. Magnesium-deficient mice have abnormalities in the hypothalamus pituitary adrenal 
(HPA) axis, leading to increased anxiety-related behaviors [156]. Since the majority of patients 
with IBS have anxiety or depression [68], magnesium assessment is justified in patients with 
FBDs.  
Other nutrients may be implicated in the pathogenesis of IBS. In zinc metabolism, 
specifically, IBS pathogenesis may follow a different course depending on the patient’s blood 
levels of zinc or the amount of fecal zinc excretion [159].  
A Swedish study [189] found that IBS patients and the general population both met 
micronutrient needs, however patients with IBS had significantly higher intake of vitamins E and 
C, folate, iron and dietary fiber but lower intake of vitamin A, riboflavin, calcium and potassium. 
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In a study done in Norway, low intake of vitamin B6 was related to severity of IBS symptoms 
[154]. Patients in the United States with IBS may or may not have similar dietary intakes 
compared to the general population. The aim of this study was to measure micronutrient levels 
(vitamins D, B6, B12, and minerals zinc, copper and magnesium) in FBD patients in an 
integrative medicine clinic at an academic medical center.  
METHODS 
This study was a retrospective chart review from an integrative medicine clinic at an 
academic medical center. Patients’ charts were selected if the patient had been diagnosed with a 
functional bowel disorder and fit study criteria. Patients included in the study were between 21 
and 89 years old, diagnosed with a FBD, and attended at least 3 appointments at KU IM. See 
Table 19 for inclusion and exclusion criteria. 
Table 19: Study inclusion and exclusion criteria. 
FBD, functional bowel disorder; IBS, irritable bowel syndrome; KU, University of Kansas. 
 
Inclusion Criteria Exclusion Criteria 
• 21-89 years of age  
• Diagnosed with a FBD (e.g. IBS, 
functional diarrhea, functional 
constipation, functional disorder of 
intestine, and/or functional bowel 
abnormality) 
• Has attended 3 or more appointments at 
KU Integrative Medicine with a 
“provider” (medical doctor, advanced 
practice registered nurse, physician 
assistant or registered dietitian)  
• Third follow up on or before May 1, 
2016 
• Only consultation at KU Medical 
Center was with a Registered Dietitian 
unless they had been previously 
diagnosed with a FBD by a diagnosing 
healthcare provider (i.e. medical doctor, 
advanced practice registered nurse, 
physician assistant) 




After screening 547 charts for study inclusion and exclusion criteria, 75 patient charts fit 
study criteria. Subsequently, a board certified gastroenterologist reviewed the records, assessed 
patient-reported symptoms and used Rome IV diagnostic criteria and determined that one patient 
did not fit study criteria. That patient was excluded from analysis. The remaining 74 patients 
were diagnosed with IBS-C (n=23), IBS-D (n=19), IBS-M (n=14), FC (n=11), FB (n=4) or FD 
(n=3).  
Micronutrient analysis 
All patients in the study had labs analyzed by one of several different laboratories, 
including Quest Diagnostics Lab (Quest Lab) (n=26), MedTox Laboratories (n=23), Lab Corp 
(n=16), NMS Laboratories (n=7), and one of two other local hospital labs (n=2). Micronutrient 
data from patients included plasma or serum zinc, serum copper, red blood cell (RBC) 
magnesium, serum vitamin D (25-hydroxy (OH)), plasma vitamin B6, and plasma or serum 
vitamin B12. Micronutrient values reported using different units of measure were converted so 
all patients’ labs were reported comparably. Patients’ baseline micronutrient status was used 
because it was common for practitioners to recommend supplementation as an intervention.  
Laboratory analysis for micronutrients was based on Quest Lab’s validated methodology 
and reference ranges since Quest Lab analyzed most patients’ labs (n=26). Quest Labs’ reference 
ranges were also used but were similar to Lab Corp and Mayo Clinic reference ranges. For 
plasma vitamin B6 (or pyridoxal-5-phosphate or “P5P”), Quest Lab used liquid 
chromatography/tandem mass spectrometry (LC/MS/MS), and the reference range for adults 18 
or older was 2.1-21.7 ng/mL. Quest Lab measured vitamin B12 (cobalamin) via immunoassay, 
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and the reference range for adults was 200-1100 pg/mL. Vitamin D (25-hydroxy-vitamin D2 + 
25-hydroxy-vitamin D3 or “25-OH-D”) was measured using Liquid Chromatography/Tandem 
Mass Spectrometry (LC/MS/MS). The reference ranges for 25-OH-D for adults were 30-100 
ng/mL. Zinc was measured via inductively coupled plasma/mass spectrometry (ICP/MS), and the 
reference range for adults was 60-130 μg/dL. Copper was measured the same way as zinc 
(ICP/MS) and the reference range was 70-175 μg /dL. Finally, RBC magnesium was measured 
via ICP/MS with a reference range between 4.0-6.4 mg/dL.  
RESULTS 
The average age of patients in this study was 50.8 years (std. dev. 12.8 years) with a 
range between 22-80 years. The majority of patients were women (n=63 or 85.1%). At baseline, 
85% of patients (n=63) were taking at least one dietary supplement, 10.8% (n=8) were not taking 
any dietary supplements, and we were unable to find data on baseline supplementation for 4.1% 
of patients (n=3).  
Out of the 74 patients who fit study criteria, serum zinc and vitamin B12 levels were 
measured in 74 patients (100%). Copper, RBC magnesium, and vitamin D levels were available 
in 73 patients (98.6%), and vitamin B6 levels were measured in 71 patients (95.9%).  
The mean RBC magnesium level of patients with FBDs at KU Integrative Medicine was 
4.9 mg/dL. The mean zinc and copper levels were 79.6 ug/dL and 119 ug/dL respectively. Mean 
25-OH vitamin D level was 43.8 ng/mL (median 37.4 ng/mL). The mean vitamin B6 level was 




Table 20: Micronutrient blood levels for copper, zinc, vitamin B6, red blood cell magnesium, 














73 (98.6%) 119 32.0 68-221 70-175       μg/dL 






79.6 15.6 48-144 60-130  μg/dL 





71 (95.9%) 42.2* 45.5 2.4-250 2.1-21.7     μg/L 
11.9     
μg/L 
Magnesium 
(mg/dL) 73 (98.6%) 4.9 0.9 3.2-8.5 
4.0-6.4 
mg/dL 




74 (100%) 691.1 429.7 172-2000 
200-1100 
pg/mL 
650    
pg/mL 
Vitamin D 
(ng/mL) 73 (98.6%) 43.8* 20.6 14-112 
30-100 
ng/mL 
65      
ng/mL 
*median vitamin B6 was 22 μg/L; median vitamin D was 37.4 ng/mL 
Most of the patients (between 74 and 94.6%) were within the Quest Lab reference range for each 
micronutrient measured except for vitamin B6 (49.3%). The percentage of patients within the 
reference range for vitamin B6 (2.1-21.7 μg/L) was 49.3% (n=35) while 50.7% (n=36) were 
above the reference range and none were below the reference range. Similarly, 11 patients 
(14.9%) had vitamin B12 levels above the reference range while only 1 patient was deficient. 
See Table 21.  
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Table 21:  Micronutrient reference ranges (per Quest Lab) with number and percentage of 
patients within the reference range, above the reference range and below the reference range. 
 Reference Range 
Within 
Reference 
Range n (%) 
> Ref. Range < Ref. Range 
Patients with 
Micronutrient 
lab results (n) 




















































 Results of micronutrient status of patients with FBDs have not been reported previously 
outside of Tazzyman [153] reporting vitamin D status in IBS patients. Our results suggest that 
micronutrient deficiency is an unlikely explanation for IBS pathophysiology with the exception 
of vitamin D deficiency as a possible component [153].  
That over half of the patients with vitamin B6 levels above the reference range is likely 
related to the majority of patients (85%) of KU IM taking dietary supplements before receiving 
an intervention. With elevated levels of vitamin B6, patients would be told by KU IM providers 
to decrease vitamin B6 via supplements. The micronutrient with the most overt deficiencies 
measured was vitamin D3, which is unsurprising given wide prevalence vitamin D deficiency 
among Americans [193]. However, our population of IM patients had a lower prevalence of 
vitamin D deficiency than the general US population (23.3% compared to 41.6%) [193].  
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Although few of the patients’ micronutrient status was deficient, IM clinicians would less 
likely depend on deficiency (formally outside of reference range) to intervene using 
supplementation; IM clinicians would likely recommend supplementation when patients’ levels 
were in the lower part of the reference range. Alternatively, measuring micronutrient status in 
patients at a general primary care or gastroenterology clinics may show different micronutrient 
results. Micronutrient lab testing is less common in these practices, likely due to unlikely 
insurance coverage and the practitioners’ limited experience with nutritional lab testing and 
subsequent interventions. 
There are several limitations of this study. First, this study was retrospective, so the 
conclusions we can draw from our findings are limited since we were unable to control for 
variables, retrospectively. Similarly, the providers in this study did not administer a standard 
diet. Most providers used laboratory testing to inform the dietary intervention. We did not 
measure the dietary intake pre- and post-intervention. Thus, our measurement of micronutrient 
adequacy was exclusively based on micronutrient levels per blood tests. 
CONCLUSIONS 
 Patients with FBDs in this IM clinic predominantly had adequate micronutrient status 
(within the Quest Lab reference ranges). However, most patients’ vitamin B6 levels and several 
patients’ vitamin B12 levels were above the reference range, most likely reflecting that most 
patients at this clinic were already taking dietary supplements.  Several patients were also below 
the reference range for Vitamin D, but fewer were deficient compared to the general U.S. 
population. The majority of patients visiting this IM clinic took dietary supplements, which may 
suggest that these patients would be at lower risk for nutritional deficiency than the general 
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population. A reasonable next step would be to measure micronutrient status in patients with 















I. Summary of findings, discussion and conclusions 
Treatment of FBDs at KU IM is primarily diet and nutrition-based. The most common 
intervention for FBD patients by IM practitioners was to recommend that patients take a vitamin 
or mineral supplement (94.6%) and then to follow an elimination diet (87.8%). Patients were 
most often suggested to avoid gluten-containing foods and ingredients (92.3%), and when added 
to suggesting a patient avoid gluten and/or grains, nearly all patients were told to avoid gluten 
(98.5%). These nutrition-based interventions seemed to contribute to improvement in GI related 
symptoms. About 75% of FBD patients reported improvement in GI symptoms using the MSQ.  
IM interventions appeared to be most effective for diarrhea-predominant FBDs. 
However, the IM interventions for the any of the FBDs did not appear to differ. This suggests 
that dietary intervention may be more effective in patients with IBS-D or FD compared to 
patients with IBS-C, FC, or FB.  
Since IBS is a complex condition with various pathophysiological mechanisms, the 
effectiveness of IM interventions for IBS may be due to the holistic nature of IM. Patients have 
appointments with providers that often last an hour, so they are able to develop a strong 
relationship with providers. Additionally, the patient feels their symptoms and experience is 
validated, and they feel listened to and like the provider believes them. This may have a 
therapeutic effect, as well. Patients also feel like they have some control over their health, and 
they can take ownership of the treatment by changing their diet. IM patients are also likely to be 
patients who would be more skeptical of conventional medical treatment, and they would have a 
stronger belief in the idea that IM therapies would be more effective.  
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In addition to the seeming effectiveness of dietary intervention, it is possible that IM 
patients have improvement in FBD symptoms due to the additional time spent by IM providers. 
This idea is supported by the fact that patients IBS patients’ negative emotions are related to their 
symptoms and the feeling that their healthcare providers do not believe the reality of their 
symptoms [161]. One way to address the patients’ needs would be that physicians validate the 
patients’ experience and subsequently refer the patient to a RDN who is skilled in administering 
dietary approaches for FBDs or to an IM clinic that has more time to listen to the patients’ 
stories. There may be a therapeutic nature of listening to the patient.  
Although Spiller and colleagues [41] suggest that the placebo effect diminishes after 12 
weeks, this is the only suggestion in the literature of the placebo effect in IBS patients. Thus, it is 
possible that the IM patients’ symptoms may have improved due to a placebo effect.  
IM patients with FBDs did not appear to have micronutrient deficiencies except for 
vitamin D deficiency, which was less common than among the general population. That patients 
had adequate micronutrient status may be due to patients taking nutritional supplements prior to 
their IM consultation. Although these IM patients were not deficient in micronutrients based on 
clinical lab reference ranges, providers in an IM clinic would likely intervene with dietary or 
supplemental recommendations when patients’ micronutrient levels were in the lower part of the 
reference range.  If patients are above the reference range, as in the case of vitamin B6, then they 
would be encouraged to decrease vitamin B6 via supplementation. 
Based on the evidence presented in this study, clinicians may feel more confident that 
dietary interventions may be warranted for FBD patients, and especially for IBS patients. Since 
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pharmaceutical interventions lack efficacy, are expensive and may come with side effects, 
dietary interventions are feasible, effective, and safe for these patients.  
The clinical significance of micronutrient testing is lacking. Our evidence suggests that 
micronutrient deficiency is an unlikely explanation for IBS or FBD pathophysiology with the 
exception of vitamin D as a possible factor [153]. More research may help determine reference 
and optimal ranges of blood micronutrient levels.  
Ideally, both primary care providers and gastroenterologists who see patients with IBS 
would first validate the patients’ experience of their symptoms. Next, since they have limited 
time, the physician can refer to a RDN who could a) spend time listening to the patients’ story 
and b) lead the patient through an elimination diet or the low FODMAP diet. This would make 
the most of the relationship between physician and patient and also allow the patient to take an 
active role in their treatment.   
II. Limitations 
The proposed study is limited in the conclusions that can be made. Since it was a 
retrospective chart review (RCR), many limitations are inherent in such a research design. I tried 
to address as many of the 10 common mistakes of RCRs as published by Vassar and Holzmann 
[194]. To address these common mistakes, I created well-defined research questions, calculated 
power to determine the number of charts to review, operationalized as many variables as 
possible, developed inclusion/exclusion criteria, and addressed ethical considerations of 
reviewing clinical charts by being reviewed by the human subjects committee at The University 
of Kansas Medical Center. Limitations that were not addressed in this study are intrerrater 
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reliability, as I was the only person abstracting data. A nursing student helped with data entry 
into excel database. I also did not perform a pilot test.  
There are other limitations of this RCR. Since all patients in this study were from KU IM, 
the study population had a self-selection bias. Additionally, the fact that I am a clinician at KU 
Integrative Medicine poses a research bias. Ideally, a person who is blinded to the study 
questions would objectively collect data based on an objective procedural manual. Also, the 
MSQ is not a validated symptom measurement tool; therefore the conclusions that can be drawn 
from this study are limited.  
Patients in an IM clinic are often seeking care because they either have had unsatisfactory 
outcomes from conventional medical treatment or they hope to find solutions without medical 
treatment. These patients would more likely be motivated to make dietary and other lifestyle 
changes than those patients who might seek conventional medical are. Thus, results from this 
study are not generalizable to the population. However, the results suggest the efficacy of 
lifestyle interventions for IBS.   
III. Future directions 
From this investigation, I will begin to describe the current treatment of FBDs in an 
integrative medical setting and identify key areas to improve practice. I can use the KU 
Integrative Medicine FBD Care Algorithm to inform future research and methods. 
A possible next step would be to look at the microbiota of patients with FBDs and 
especially those who had worsening or unchanged GI symptoms. Since evidence suggests that 
IBS patients have altered microbiota compared to people without IBS [195 196] it would be 
important to investigate.  
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Another possible research direction would be to consider the combined impact of food 
elimination with other interventions, like acupuncture, psychotherapy, and supplementation like 
peppermint oil, medications, or other therapies. We might also investigate which foods are most 
effective at alleviating FBD-related symptoms, that when eliminated we would continue to meet 
the patient’s nutritional needs.  
In a recent Lancet review, Holtmann and colleagues [2] make clear the importance to 
further characterize the pathophysiology of IBS. Clarification of pathophysiology will allow a 
transition away from symptom-based approaches to IBS. Mounting evidence for 
pathophysiology (suggesting organic disease) demonstrates abnormalities in patients’ 
microbiota, serotonin metabolism, bile salt metabolism, post-infectious and chronic infection-
related symptoms, diet-induced symptoms, inflammation, and others [2]. When we approach IBS 
solely based on symptoms (diarrhea, constipation, bloating), we may group and treat patients 
similarly who actually have heterogeneous pathophysiology. By addressing the physically 
measurable abnormalities in these patients, we might get closer to a curative versus treatment 
approach. Measuring the microbiota, food sensitivities, and other nutrition or diet-related aspects 
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